0001607062-24-000131.txt : 20240424 0001607062-24-000131.hdr.sgml : 20240424 20240424132750 ACCESSION NUMBER: 0001607062-24-000131 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regen BioPharma Inc CENTRAL INDEX KEY: 0001589150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 455192997 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-191725 FILM NUMBER: 24869446 BUSINESS ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 BUSINESS PHONE: 619-722-5505 MAIL ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 10-Q 1 rgbp033124form10q.htm 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	45-5192997
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 722-5505

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☒ Non-accelerated filer	☒ Smaller reporting company
	☐ Emerging Growth Company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of March 31, 2024 Regen Biopharma, Inc. had 4,114,622 common shares outstanding.

As of March 31, 2024 Regen Biopharma, Inc. had 409,551 shares of Series A Preferred Stock outstanding.

As of March 31, 2024 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding.

As of March 31, 2024 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding.

As of March 31, 2024 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

		As of
		March 31, 2024			September 30, 2023
		(unaudited)
ASSETS
CURRENT ASSETS
Cash	$	78,115		$	121,037
Accounts Receivable, Related Party		39,723			0
Note Receivable, Related Party					0
Prepaid Expenses		200			0
Prepaid Rent		5,000			10,000
Total Current Assets		123,037			131,037
Investment Securities, Related Party		17,733			222,580
Total Other Assets		17,733			222,580
Total Assets	$	140,770		$	353,617

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		29,798			29,674
Notes Payable		49,210			95,710
Accrued payroll taxes		4,241			4,241
Accrued Interest		342,416			342,588
Accrued Payroll		1,256,630			1,256,630
Other Accrued Expenses		41,423			41,423
Bank Overdraft		1,000			1,000
Due to Investor		20,000			20,000
Unearned Income		1,528,451			1,591,731
Unearned Income (Related Party)		0			15,126
Derivative Liability		1,400,000			1,400,000
Convertible Notes Payable Less unamortized discount		499,880			499,880
Convertible Notes Payable, Related Parties Less unamortized discount		0			10,000
Total Current Liabilities		5,173,049			5,308,003
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount
Notes Payable		143,685			149,614
Total Long Term Liabilities		143,685			149,614
Total Liabilities		5,316,734			5,457,617

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,114,622 issued and outstanding as of March 31, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023.		412			352
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of March 31, 2024 and September 30, 2023 respectively		40			40
Series A Preferred; 739,000,000 authorized as of September 30, 2023 and March 31, 2024; 409,551 outstanding as of March 31, 2024 and September 30, 2023		40			40
Series AA Preferred; $0.0001 par value 600,000 authorized and 34 and 34 outstanding as of March 31, 2024 and September 30,2023 respectively		0			0
Series M Preferred; $0.0001 par value 60,000,000 authorized and 29,338 outstanding as of September 30, 2023 and 60,000,000 authorized and 29,338 outstanding as of March 31, 2024		3			3
Series NC Preferred; $0.0001 par value 20,000 authorized and 15,007 outstanding as of September 30, 2023 and March 31, 2024		2			2
Additional Paid in capital		14,308,349			13,908,141
Contributed Capital		736,326			736,326
Retained Earnings (Deficit)		(20,221,096	)		(19,748,863	)
Total Stockholders' Equity (Deficit)		(5,175,963	)		(5,104,000	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	140,770		$	353,617

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	Quarter Ended March 31, 2024			Quarter Ended March 31, 2023			Six Months Ended March 31, 2024			Six Months Ended March 31, 2023
REVENUES
Revenues	$	31,640		$	31,640		$	63,280		$	63,280
Revenues, Related Party		27,425			27,425			54,849			54,849
TOTAL REVENUES		59,065			59,065			118,129			118,129

COST AND EXPENSES
Research and Development		40,133			36,446			87,661			131,959
General and Administrative		9,387			18,660			21,806			27,398
Consulting and Professional Fees		93,400			67,800			200,300			471,480
Rent		17,215			15,000			32,215			30,000
Total Costs and Expenses		160,135			137,906			341,981			660,837
OPERATING INCOME (LOSS)	$	(101,071	)	$	(78,842	)	$	(223,852	)	$	(542,708	)

OTHER INCOME & (EXPENSES)
Interest Expense		(17,063	)		(12,085	)		(34,828	)		(29,444	)
Interest Expense attributable to Amortization of Discount		(4,339	)					(8,706	)
Unrealized Gain ( Loss) on sale of Investment Securities								(204,847	)
Derivative Income (Expense)					35,949						2,151,755
Gain (Loss) on Extinguishment Convertible Debt											1,150
TOTAL OTHER INCOME (EXPENSE)		(21,402	)		23,864			(248,380	)		2,123,460
NET INCOME (LOSS)	$	(122,473	)		(54,978	)	$	(472,233	)	$	1,580,752
NET INCOME (LOSS) attributable to common shareholders	$	(122,473	)		(54,978	)	$	(472,233	)	$	1,391,061

BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$	(0.03	)	$	(0.03	)	$	(0.12	)	$	0.41
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		3941013			1656429			3831431			3364578

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT)

(unaudited)


Six Months Ended March 31, 2024

		Series A Preferred				Series AA Preferred				Series NC Preferred				Common				Series M Preferred
		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital			Retained Earnings			Contributed Capital			Total
Balance September 30, 2023			409,551	$	40		34	$	0		15,007	$	2		3,506,366	$	352		29,338		3	$	13,908,141		$	(19,748,863	)	$	736,326	$	(5,104,000		)
10/13/2023	Common Shares issued for Cash				—				—				—		16,710		2				—		22,724			—			—		22,726
10/27/2023	Common Shares issued for Cash				—				—				—		35,785		4				—		46,088			—			—		46,091
11/10/2023	Common Shares issued for Cash				—				—				—		31,732		3				—		38,202			—			—		38,205
11/27/2023	Common Shares issued for Cash				—				—				—		33,989		3				—		32,626			—			—		32,629
12/11/2023	Common Shares issued for Cash				—				—				—		43,297		4				—		38,097			—			—		38,101
12/20/2023	Common Shares issued for Cash				—				—				—		82,686		8				—		34,535			—			—		34,543
Net Income (Loss) Quarter Ended December 31, 2023					—				—				—		—		—				—		—			(349,760	)		—		(349,760	)
Balance December 31, 2023			409,551	$	40		34	$	0		15,007		2		3,750,565		376		29,338		3		14,120,412			(20,098,623	)		736,326	$	(5,241,463	)
1/3/2024	Common Shares issued for Cash				—				—				—		94,883		9				—		39,629			—			—		39,638
1/10/2024	Common Shares issued for Cash				—				—				—		82,643		8				—		44,288			—			—		44,297
2/2/2024	Common Shares issued for Cash				—				—				—		40,229		4				—		19,609			—			—		19,614
2/21/2024	Common Shares issued for Cash				—				—				—		52,569		5				—		32,356			—			—		32,362
3/6/2023	Common Shares issued for Cash				—				—				—		44,503		4				—		25,278			—			—		25,282
3/20/2024	Common Shares issued for Cash				—				—				—		49,230		5				—		26,776			—			—		26,781
Net Income (Loss) Quarter Ended March 31, 2024					—				—				—		—		—				—		—			(122,473	)		—		(122,473	)
Balance March 31, 2024			409,551	$	40		34	$	0		15,007		2		4,114,622		413		29,338		3		14,308,349			(20,221,096	)		736,326	$	(5,175,963	)

Six Months Ended March 31, 2023

			Series A Preferred				Series AA Preferred				Series NC Preferred				Common				Series M Preferred
			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital			Retained Earnings			Contributed Capital		Total
Balance September 30, 2022			293,053	$	28		34	$	0		7	$	—		3,354,886	$	335		29,338	$	3	$	12,132,620		$	(20,905,369	)	$	736,326	$	(8,036,059	)
10/25/2022	Preferred Shares Issued for Nonemployee Services		6,667	$	1				—				—				—				—		299,999			—			—		$300,000
11/11/2022	Preferred Shares Issued for Debt		70,114	$	7				—				—				—				—		761,493			—			—		$761,500
11/11/2022	Preferred Shares Issued for Interest		35,012	$	4				—				—				—				—		380,258			—			—		$380,262
11/11/2022	Common Shares Issued For Interest				—				—				—		11,279	$	1				—		25,368			—			—		25,369
12/5/2022	Preferred Shares Issued for Nonemployee Services		1,112	$	0				—				—				—				—		48,372			—			—		$48,372
Net Income for the Quarter ended December 31, 2022					—				—				—				—				—		—			1,635,730			—		1,635,730
Balance December 31, 2022			405,958	$	40		34	$	0		7	$	—		3,366,165	$	337		29,338		3	$	13,648,107		$	(19,269,640	)	$	736,326	$	(4,884,827	)
3/13/2023	Common Shares issued pursuant to round up provision				—				—				—				—				—		—			—			—		—
	March 6,2023 reverse stock split				—				—				—		15,201	$	2				—		(2	)		—			—		0
3/13/2023	Preferred Shares issued pursuant to round up provision				—				—				—				—				—		—			—			—		—
	March 6,2023 reverse stock split		3,593		—				—				—				—				—		—			—			—		—
3/17/2023	Preferred Shares issued for accrued salaries				—				—		15,000		2				—				—		10,048			—			—		10,050
Net Income (Loss) for the Quarter Ended March 31, 2023					—				—				—				—				—		—			(54,978	)		—		(54,978	)
Balance March 31, 2023			409,551	$	40		34	$	0		15,007	$	2		3,381,366	$	339		29,338		3	$	13,658,153		$	(19,324,617	)	$	736,326	$	(4,929,755	)

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA , INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)


	Six Months Ended			Six Months Ended
	March 31,2024			March 31,2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	(472,233	)	$	1,580,752
Adjustments to reconcile net Income to net cash
Preferred Stock issued as compensation					348,372
Increase (Decrease) in Interest expense attributable to amortization of Discount		8,706
Increase (Decrease) in Accounts Payable		124			5,248
(Increase) Decrease in Accounts Receivable		(39,723	)		175,150
Increase (Decrease) in accrued Expenses		(171	)		29,444
(Increase) Decrease in Prepaid Expenses		5,200			13,714
Increase(Decrease) in Contributed Capital		0
Increase ( Decrease) in Derivative Expense		0			(2,151,755	)
Increase ( Decrease) in Unearned Income		(78,407	)		(63,280	)
(Gain) Loss on forgiveness of Debt		0			(1,150	)
Unrealized Loss (Gain) on Investment Securities		204,847
Net Cash Provided by (Used in) Operating Activities	$	(371,657	)	$	(63,504	)

CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Convertible Notes Payable		(10,000	)
Increase (Decrease) in Notes Payable		(61,500	)		100,000
Increase (Decrease) in Common Stock issued for cash		400,234
Net Cash Provided by (Used in) Financing Activities		328,734			100,000
Net Increase (Decrease) in Cash	$	(42,923	)	$	36,949

Cash at Beginning of Period	$	121,037		$	51,204
Cash at End of Period	$	78,114		$	87,700

Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt
Preferred Shares Issued for Debt				$	761,500
Cash Paid for Interest
Common shares Issued for Interest				$	25,369
Preferred Shares issued for Interest				$	380,262

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of March 31, 2024

These Notes have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease.

The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated.

The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31, 2024 utilized the following inputs:

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(1.70) – (4.08) Yrs
Expected Volatility	932.98	%
Expected Dividends

H. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2023 and March 31, 2024.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products.

The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019.

In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company has adopted ASU 2020-06 as of the Fiscal Year ending September 30, 2022.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,221,096 during the period from April 24, 2012 (inception) through March 31, 2024. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC (“Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”).

Under the terms of the Equity Line Agreement, Coventry will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Coventry’s resale of any Common Stock purchased by Coventry under the Equity Line.

From time to time over the 36-month term of the Commitment Period ( as such term is defined in the Equity Line Agreement) the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 80% of the lowest trading price of the Common Stock during the ten business days prior to the Draw Down Notice date (the “Pricing Period”).

The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value (as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company.

The Company issued Coventry 125,000 shares of its Common Stock in connection with the Equity Line Agreement.

Coventry has agreed that:

(a)

for so long as the market price of the Company’s common stock is above $1.25 per share and

(b)

the Company is in full compliance with all agreements entered into with Coventry and

(c)

and the Company has not issued any common shares at a per share price below $1.50, Coventry will agree to a leak out provision and will not sell more than 10,000 shares of the Commitment shares without permission from the Issuer.

In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement as well as the aforementioned 125,000 common shares issued in connection with the Equity Line Agreement in a Registration Statement to be filed with the Securities and Exchange Commission. Up to 1,126,954 Shares of Common Stock were registered for resale under the Securities Act of 1933 pursuant to the Registration Rights Agreement.

During the quarter ended December 31, 2023 the Company issued 244,199 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $212,296. During the Quarter ended March 31, 2024 the Company issued 364,057 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $187,937.

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Notes payable related party
	As of March 31, 2024
David Koos	$	710
Total:	$	710

$710 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

(b) NON RELATED PARTY As of March 31, 2024

Schedule of non related party
Bostonia Partners, Inc	$	100.000
Total:	$	100,000

$48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of 10% per annum.

Effective September 12, 2023 Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000 of which $26,250 was retained by Coventry through an Original Issue Discount.

The Note carries “Guaranteed Interest” on the principal amount at the rate of 10% per annum for the eighteen-month term of the Note for an aggregate Guaranteed Interest $26,250. The Principal Amount and the Guaranteed Interest shall be due and payable in seven equal monthly payments of $28,750 commencing on August 12, 2024 and continuing on the 12th day of each month thereafter until paid in full not later than March 12, 2025(the “Maturity Date”).

Upon an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder at price per share equivalent to 90% of the lowest per-share trading price for the 20 Trading Days preceding a Conversion Date.

Upon the event that while this Note has been outstanding for four months, the Company consummates another financing transaction or if the Company has an effective Regulation A Offering Statement then the Investor may choose to convert any amount up to the entire balance of the note including guaranteed interest into shares at the same offering price as the aforementioned financing transaction or the Regulation A Offering. The outstanding principal balance of the Note is $160,000 as of March 31, 2024.

NOTE 5. CONVERTIBLE NOTES PAYABLE

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities.

The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

As of March 31, 2024 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of March 31, 2024 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

As of March 31, 2024 $50,000 of the principal amount of the Note remains outstanding

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $375 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $75 per share.

The warrants shall be exercisable:

In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”)

In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note

As of March 31, 2024 $200,000 of the principal amount of the Note remains outstanding.

The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,000 was recognized by the Company as of March 31, 2024.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.50 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

(ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of March 31, 2024 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,000 was recognized by the Company as of March 31, 2024.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.5 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of March 31, 2024, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of March 31, 2024.

NOTE 6. RELATED PARTY TRANSACTIONS

On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company.

Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by The Company:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.

Zander and Regen are under common control.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date.

Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen.

As of March 31, 2024, $0 of the principal amount of the Note remains outstanding and all accrued interest has been paid.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275 and during the quarter ended June 30, 2022 Dr. Brian Koos was paid $36,975. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company.

As of March 31, 2024 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $710. $710 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022.

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

NOTE 7. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of March 31, 2024:

Common stock, $ 0.0001 par value; 5,800,000,000 shares authorized: 4,114,622 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of March 31, 2024, 739,000,000 is designated Series A Preferred Stock of which 409,551 shares are outstanding as of March 31, 2024, 60,000,000 is designated Series M Preferred Stock of which 29,338 shares are outstanding as of March 31, 2024, and 20,000 is designated Series NC stock of which 15,007 shares are outstanding as of March 31, 2024.

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

Series AA Preferred Stock

On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).

The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times seven (7). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Series A Preferred Stock

On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”).

The Board of Directors of the Company have authorized 739,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series M Preferred Stock” (hereinafter referred to as “Series M Preferred Stock”).

The Board of Directors of Regen have authorized 60,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as “Series NC Preferred Stock”).

The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 334. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.

On March 31, 2024 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:

Dividend income
Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40,000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders		708,916
Fair Value Per Share	$	0.0155

The abovementioned constitute the Company’s sole related party investment securities as of March 31, 2024.

As of March 31, 2024:

	Comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024
$	5,741	$	6,496	$	755	$	(0	)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024
$	13,124	$	11,238	$	(1,866	)	$	(0	)

NOTE 9. STOCK TRANSACTIONS

On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638.

On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $44,297.

On February 2, 2024 the Company issued 40,229 common shares for cash consideration of $19,614.

On February 21, 2024 the Company issued 52,569 common shares for cash consideration of $32,362.

On March 6, 2024 the Company issued 44,503 common shares for cash consideration of $25,282.

On March 20, 2024 the Company issued 49,230 common shares for cash consideration of $26,781.

NOTE 10. SUBSEQUENT EVENTS

On April 3, 2024 the Company issued 52,763 common shares for cash consideration of $25,326.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

As of March 31, 2024 we had cash of $78,115 and as of September 30, 2023 we had cash of $121,037. The decrease in cash of approximately 35% is primarily attributable to cash expended in the aperation of the Company’s business as well as payments of principal amounts due on Notes Payable , Convertible Notes Payable ( Related Party) and accrued interest due on Convertible Notes Payable ( Related Party) offset by $400,000 paid to the Company from sales of common stock of the Company for cash.

As of March 31, 2024 we had Accounts Receivable, Related Party of $39,723 and as of September 30, 2023 we had Accounts Receivable, Related Party of $0. Accounts Receivable, Related Party as of March 31, 2024 consists of fees accrued but not yet paid pursuant to a license granted to Zander Therapeutics, Inc. by Regen Biopharma, Inc. Zander Therapeutics, Inc. and the Company are under common control.

As of March 31, 2024 we had Prepaid Expenses of $200 and as of September 30, 2023 we had Prepaid Expenses of $0. Prepaid Expenses of $200 as of March 31, 2024 is attributable to an overpayment of $200 paid to a patent attorney.

As of March 31, 2024 we had Prepaid Rent of $5,000 and as of September 30, 2023 we had Prepaid Rent of $10,000. The decrease in Prepaid Rent of 50% is attributable to the cash payment by the Company of $10,000 out of $15,000 rent expenses incurred during the quarter ended December 31, 2023.

As of March 31, 2024 we had Investment Securities (Related Party) of $17,733 and as of September 30, 2023 we had Investment Securities (Related Party) of $222,580. During the six months ended March 31, 2024 the Company revalued its owned shares of Zander Therapeutics, Inc. resulting in the recognition of a decrease in fair value of 92.3% as compared to September 30, 2023.

As of March 31, 2024 we had Current Notes Payable of $49,210 and as of September 30, 2023 we had Current Notes Payable of $95,710. The reduction in Current Notes Payable of approximately 48.6% is attributable to repayment of $46,500 of outstanding principal indebtedness during the quarter ended December 31, 2023.

As of March 31, 2024 we had Convertible Notes Payable, Related Parties of $0 and as of March 31, 2024 we had Convertible Notes Payable, Related Parties of $10,000. $10,000 due and payable to Zander Therapeutics, Inc. was paid during the quarter ended March 31, 2024. Zander Therapeutics, Inc. and the Company are under common control.

On March 31, 2024 we had Unearned Income, Related Party of $0 and as of September 30, 2023 we had Unearned Income, Related Party of $15,126. Unearned Income (Related Party) as of September 30, 2023 consisted solely of licensing fees paid to the Company by Zander Therapeutics, Inc. but not yet earned. These fees were earned during the quarter ended December 31, 2023. Zander Therapeutics, Inc. and the Company are under common control.

Revenues from continuing operations were $59,065 for the quarter ended March 31, 2024 and $59,065 for the same period ended 2023. $27,425 of revenue from related parties recognized during the three months ended March 31, 2024 and March 31, 2023 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and minimum royalties recognized during the three months ended March 31, 2023 and 2024 respectively pursuant to the same license. $31,640 of revenue recognized during the three months ended March 31, 2024 were recognized pursuant to licenses granted to Oncology Pharma,Inc. and $31,640 of revenue was recognized during the quarter ended March 31 , 2023 pursuant to those same licenses.

The Company recognized an Operating Loss of $101,071 during the quarter ended March 31, 2024 whereas the Company recognized an Operating Loss of $78,842 for the same period ended 2023. The disparity in Operating Losses is primarily attributable to greater Research and Development and Consulting Expenses recognized during the quarter ended March 31, 2024 as compared to the same quarter ended 2023. The Company recognized a Net Loss of $ 122,473 during the quarter ended March 31, 2024 whereas the Company recognized a Net Loss of $54,978 during the quarter ended March 31, 2023. The disparity in Net Losses is primarily attributable to the recognition of $35,949 in Derivative Income recognized during the quarter ended March 31, 2023.

Revenues from continuing operations were $118,129 for the six months ended March 31, 2024 and $118,129 for the same period ended 2023. $54,849 of revenue from related parties recognized during the six months ended March 31, 2024 and March 31, 2023 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and minimum royalties recognized during the six months ended March 31, 2023 and 2024 respectively pursuant to the same license. $63,280 of revenue recognized during the six months ended March 31, 2024 were recognized pursuant to licenses granted to Oncology Pharma,Inc. and $63,280 of revenue was recognized during the six months ended March 31 , 2023 pursuant to those same licenses.

The Company recognized an Operating Loss of $ 223,852 during the six ended March 31, 2024 whereas the Company recognized an Operating Loss of $542,708 for the same period ended 2023. The disparity in Operating Losses is primarily attributable to greater Research and Development and Consulting Expenses recognized during the six months ended March 31, 2023 as compared to the same quarter ended 2024. The Company recognized a Net Loss of $ 248,380 during the six months ended March 31, 2024. The Company recognized Net Income of $2,123,460 during the six months ended march 31, 2023 primarily attributable to the recognition of $2,151,755 during the six months ended March 31, 2024.

As of March 31, 2024 we had $78,115 in cash on hand and current liabilities of $5,173,049 such liabilities materially consisting of Accounts Payable, Notes Payable, Convertible Notes Payable, Derivative Liability Recognized, Unearned Income and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC ( “Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”).

The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value ( as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company.

During the quarter ended December 31, 2023 the Company sold 244,199 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $212,297.

During the quarter ended March 31, 2024 the Company sold 364,057 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $187,973.

On April 3, 2024 the Company sold 52,763 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $25,326.

As of March 31 2024 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company’s internal controls during the period commencing on January 1, 2024 and ending on March 31, 2024, David Koos, who serves as the Company’s Principal Executive Officer , Principal Financial Officer has determined that there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the quarter ended March 31, 2024.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission Of Matters To A Vote Of Security Holders

None.

Item 5. Other Information

None.

Item 6. Exhibit Index

Exhibit No.	Description
31.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
31.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
32.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
32.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Regen Biopharma, Inc.

By: /s/ David R. Koos

Name: David R. Koos

Title: Chairman, Chief Executive Officer

Date: April 24, 2024

Regen Biopharma, Inc.

By: /s/ David R. Koos

Name: David R. Koos

Title: Acting Chief Financial Officer, Director

Date: April 24, 2024

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2024 of Regen Biopharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant’s, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 24, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Exeuctive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2024 of Regen Biopharma, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 24, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Regen Biopharma, Inc. on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 24, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 24, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-101.SCH 6 rgbp-20240331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTES PAYABLE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCK TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rgbp-20240331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rgbp-20240331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rgbp-20240331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series AA Preferred Stock Series M Preferred Stock [Member] Series N C [Member] Equity Components [Axis] Preferred Stock Series A [Member] Series N C Preferred Stock [Member] Common Stock [Member] Series M Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Contributed Capital [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Equity Line Agreement [Member] Legal Entity [Axis] Coventry Enterprises L L C [Member] Debt Instrument [Axis] David Koos [Member] Related And Nonrelated Party Status [Axis] Related Party [Member] Bostonia [Member] Long-Term Debt, Type [Axis] Due And Payable March 102024 [Member] Unsecured Promissory Note [Member] Nonrelated Party [Member] Convertible Note; March 8, 2016 Convertible Note; April 6, 2016 October 312016 [Member] Convertible Note; May 5, 2017 Convertible Note; December 20, 2017 Convertible Note; October 3, 2017 Convertible Note; September 30, 2018 Zander Therapeutics Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Accounts Receivable, Related Party Note Receivable, Related Party Prepaid Expenses Prepaid Rent Total Current Assets Investment Securities, Related Party Total Other Assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Notes Payable Accrued payroll taxes Accrued Interest Accrued Payroll Other Accrued Expenses Bank Overdraft Due to Investor Unearned Income Unearned Income (Related Party) Derivative Liability Convertible Notes Payable Less unamortized discount Convertible Notes Payable, Related Parties Less unamortized discount Total Current Liabilities Long Term Liabilities: Convertible Notes Payable, Related Parties Less unamortized discount Notes Payable Total Long Term Liabilities Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,114,622 issued and outstanding as of March 31, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023. Preferred Stock, 0.0001 par value, 800,000,000 authorized as of March 31, 2024 and September 30, 2023 respectively Additional Paid in capital Contributed Capital Retained Earnings (Deficit) Total Stockholders' Equity (Deficit) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Outstanding Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Outstanding Income Statement [Abstract] REVENUES Revenues Revenues, Related Party TOTAL REVENUES COST AND EXPENSES Research and Development General and Administrative Consulting and Professional Fees Rent Total Costs and Expenses OPERATING INCOME (LOSS) OTHER INCOME & (EXPENSES) Interest Expense Interest Expense attributable to Amortization of Discount Unrealized Gain ( Loss) on sale of Investment Securities Derivative Income (Expense) Gain (Loss) on Extinguishment Convertible Debt TOTAL OTHER INCOME (EXPENSE) NET INCOME (LOSS) NET INCOME (LOSS) attributable to common shareholders BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Beginning balance, value 10/13/2023 10/27/2023 11/10/2023 11/27/2023 12/11/2023 12/20/2023 Net Income (Loss) 1/3/2024 1/10/2024 2/2/2024 2/21/2024 3/6/2023 3/20/2024 Shares, Outstanding 3/13/2023 March 6,2023 reverse stock split 3/13/2023 March 6,2023 reverse stock split 3/17/2023 Stock Issued During Period, Shares, Other EX-101.PRE 10 rgbp-20240331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover	6 Months Ended
Cover	Mar. 31, 2024 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	333-191725
Entity Registrant Name	REGEN BIOPHARMA, INC.
Entity Central Index Key	0001589150
Entity Tax Identification Number	45-5192997
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	St 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	619
Local Phone Number	722-5505
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	4,114,622

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
CURRENT ASSETS
Cash	$ 78,115	$ 121,037
Accounts Receivable, Related Party	39,723	0
Note Receivable, Related Party		0
Prepaid Expenses	200	0
Prepaid Rent	5,000	10,000
Total Current Assets	123,037	131,037
Investment Securities, Related Party	17,733	222,580
Total Other Assets	17,733	222,580
Total Assets	140,770	353,617
Current Liabilities:
Accounts payable	29,798	29,674
Notes Payable	49,210	95,710
Accrued payroll taxes	4,241	4,241
Accrued Interest	342,416	342,588
Accrued Payroll	1,256,630	1,256,630
Other Accrued Expenses	41,423	41,423
Bank Overdraft	1,000	1,000
Due to Investor	20,000	20,000
Unearned Income	1,528,451	1,591,731
Unearned Income (Related Party)	0	15,126
Derivative Liability	1,400,000	1,400,000
Convertible Notes Payable Less unamortized discount	499,880	499,880
Convertible Notes Payable, Related Parties Less unamortized discount	0	10,000
Total Current Liabilities	5,173,049	5,308,003
Long Term Liabilities:
Notes Payable	143,685	149,614
Total Long Term Liabilities	143,685	149,614
Total Liabilities	5,316,734	5,457,617
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,114,622 issued and outstanding as of March 31, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023.	412	352
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of March 31, 2024 and September 30, 2023 respectively	40	40
Additional Paid in capital	14,308,349	13,908,141
Contributed Capital	736,326	736,326
Retained Earnings (Deficit)	(20,221,096)	(19,748,863)
Total Stockholders' Equity (Deficit)	(5,175,963)	(5,104,000)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 140,770	$ 353,617

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Sep. 30, 2023
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	5,800,000,000	5,800,000,000
Common Stock, Shares, Outstanding	4,114,622	3,506,366
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	739,000,000	739,000,000
Preferred Stock, Shares Outstanding	409,551	409,551
Series AA Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	600,000	600,000
Preferred Stock, Shares Outstanding	34	34
Series M Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	60,000,000	60,000,000
Preferred Stock, Shares Outstanding	29,338	29,338
Series N C [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	20,000	20,000
Preferred Stock, Shares Outstanding	15,007	15,007

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
REVENUES
Revenues	$ 31,640	$ 31,640	$ 63,280	$ 63,280
Revenues, Related Party	27,425	27,425	54,849	54,849
TOTAL REVENUES	59,065	59,065	118,129	118,129
COST AND EXPENSES
Research and Development	40,133	36,446	87,661	131,959
General and Administrative	9,387	18,660	21,806	27,398
Consulting and Professional Fees	93,400	67,800	200,300	471,480
Rent	17,215	15,000	32,215	30,000
Total Costs and Expenses	160,135	137,906	341,981	660,837
OPERATING INCOME (LOSS)	(101,071)	(78,842)	(223,852)	(542,708)
OTHER INCOME & (EXPENSES)
Interest Expense	(17,063)	(12,085)	(34,828)	(29,444)
Interest Expense attributable to Amortization of Discount	(4,339)		(8,706)
Unrealized Gain ( Loss) on sale of Investment Securities			(204,847)
Derivative Income (Expense)		35,949		2,151,755
Gain (Loss) on Extinguishment Convertible Debt				1,150
TOTAL OTHER INCOME (EXPENSE)	(21,402)	23,864	(248,380)	2,123,460
NET INCOME (LOSS)	(122,473)	(54,978)	(472,233)	1,580,752
NET INCOME (LOSS) attributable to common shareholders	$ (122,473)	$ (54,978)	$ (472,233)	$ 1,391,061
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.03)	$ (0.03)	$ (0.12)	$ 0.41
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	3,941,013	1,656,429	3,831,431	3,364,578

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Series AA Preferred Stock	Series N C Preferred Stock [Member]	Common Stock [Member]	Series M Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	Total
Beginning balance, value at Sep. 30, 2022	$ 28	$ 0		$ 335	$ 3	$ 12,132,620	$ (20,905,369)	$ 736,326	$ (8,036,059)
Net Income (Loss)							1,635,730		1,635,730
10/25/2022	$ 1					299,999			300,000
Preferred Shares Issued for Nonemployee Services, Shares	6,667
11/11/2022	$ 7					761,493			761,500
Preferred Shares Issued for Debt, Shares	70,114
11/11/2022	$ 4					380,258			380,262
Preferred Shares Issued for Interest, Shares	35,012
11/11/2022				$ 1		25,368			25,369
Common Shares Issued For Interest, Shares				11,279
12/5/2022	$ 0					48,372			48,372
PreferredSharesIssuedForNonemployeeServicesShares1	1,112
Ending balance, value at Dec. 31, 2022	$ 40	0		337	3	13,648,107	(19,269,640)	736,326	(4,884,827)
Net Income (Loss)							(54,978)		(54,978)
3/13/2023
				$ 2		(2)			0
March 6,2023 reverse stock split				15,201
3/13/2023

March 6,2023 reverse stock split	3,593
3/17/2023			2			10,048			10,050
Stock Issued During Period, Shares, Other				15,000
Ending balance, value at Mar. 31, 2023	40	0	2	$ 339	3	13,658,153	(19,324,617)	736,326	(4,929,755)
Beginning balance, value at Sep. 30, 2023	40	0	2	352	3	13,908,141	(19,748,863)	736,326	(5,104,000)
10/13/2023				2		22,724			22,726
10/27/2023				4		46,088			46,091
11/10/2023				3		38,202			38,205
11/27/2023				3		32,626			32,629
12/11/2023				4		38,097			38,101
12/20/2023				8		34,535			34,543
Net Income (Loss)							(349,760)		(349,760)
Ending balance, value at Dec. 31, 2023	40	0	2	376	3	14,120,412	(20,098,623)	736,326	(5,241,463)
Net Income (Loss)							(122,473)		(122,473)
1/3/2024				9		39,629			39,638
1/10/2024				8		44,288			44,297
2/2/2024				4		19,609			19,614
2/21/2024				5		32,356			32,362
3/6/2023				4		25,278			25,282
3/20/2024				5		26,776			26,781
Ending balance, value at Mar. 31, 2024	$ 40	$ 0	$ 2	$ 413	$ 3	$ 14,308,349	$ (20,221,096)	$ 736,326	$ (5,175,963)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) - shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Statement of Stockholders' Equity [Abstract]
[custom:SharesIssuedForCashShares]		16,710
[custom:SharesIssuedForCashShares2]		35,785
[custom:SharesIssuedForCashShares3]		31,732
[custom:SharesIssuedForCashShares4]		33,989
[custom:SharesIssuedForCashShares5]		43,297
[custom:SharesIssuedForCashShares6]		82,686
[custom:SharesIssuedForCashShares7]	94,883
[custom:SharesIssuedForCashShares8]	82,643
[custom:SharesIssuedForCashShares9]	40,229
[custom:SharesIssuedForCashShares10]	52,569
[custom:SharesIssuedForCashShares11]	44,503
[custom:SharesIssuedForCashShares12]	49,230

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (472,233)	$ 1,580,752
Adjustments to reconcile net Income to net cash
Preferred Stock issued as compensation		348,372
Increase (Decrease) in Interest expense attributable to amortization of Discount	8,706
Increase (Decrease) in Accounts Payable	124	5,248
(Increase) Decrease in Accounts Receivable	(39,723)	175,150
Increase (Decrease) in accrued Expenses	(171)	29,444
(Increase) Decrease in Prepaid Expenses	5,200	13,714
Increase(Decrease) in Contributed Capital	0
Increase ( Decrease) in Derivative Expense	0	(2,151,755)
Increase ( Decrease) in Unearned Income	(78,407)	(63,280)
(Gain) Loss on forgiveness of Debt	0	(1,150)
Unrealized Loss (Gain) on Investment Securities	204,847
Net Cash Provided by (Used in) Operating Activities	(371,657)	(63,504)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Convertible Notes Payable	(10,000)
Increase (Decrease) in Notes Payable	(61,500)	100,000
Increase (Decrease) in Common Stock issued for cash	400,234
Net Cash Provided by (Used in) Financing Activities	328,734	100,000
Net Increase (Decrease) in Cash	(42,923)	36,949
Cash at Beginning of Period	121,037	51,204
Cash at End of Period	$ 78,114	87,700
Supplemental Disclosure of Noncash investing and financing activities:
Preferred Shares Issued for Debt		761,500
Common shares Issued for Interest		25,369
Preferred Shares issued for Interest		$ 380,262

XML 19 R8.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

A. BASIS OF ACCOUNTING

B. PRINCIPLES OF CONSOLIDATION

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(1.70) – (4.08) Yrs
Expected Volatility	932.98	%
Expected Dividends

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2023 and March 31, 2024.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

XML 20 R9.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Mar. 31, 2024

Accounting Changes and Error Corrections [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

+ Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

GOING CONCERN

6 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3. GOING CONCERN

The Company issued Coventry 125,000 shares of its Common Stock in connection with the Equity Line Agreement.

Coventry has agreed that:

(a)

for so long as the market price of the Company’s common stock is above $1.25 per share and

(b)

the Company is in full compliance with all agreements entered into with Coventry and

(c)

XML 22 R11.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

6 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Notes payable related party
	As of March 31, 2024
David Koos	$	710
Total:	$	710

$710 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

(b) NON RELATED PARTY As of March 31, 2024

Schedule of non related party
Bostonia Partners, Inc	$	100.000
Total:	$	100,000

$48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of 10% per annum.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

6 Months Ended

Mar. 31, 2024

Convertible Notes Payable

CONVERTIBLE NOTES PAYABLE

NOTE 5. CONVERTIBLE NOTES PAYABLE

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of March 31, 2024 $100,000 of the principal amount of the Note remains outstanding.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of March 31, 2024 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share.

As of March 31, 2024 $50,000 of the principal amount of the Note remains outstanding

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of March 31, 2024 $200,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,000 was recognized by the Company as of March 31, 2024.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of March 31, 2024 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,000 was recognized by the Company as of March 31, 2024.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of March 31, 2024, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of March 31, 2024.

XML 24 R13.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

6 Months Ended

Mar. 31, 2024

RELATED PARTY TRANSACTIONS

NOTE 6. RELATED PARTY TRANSACTIONS

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

The Agreement may be terminated by The Company:

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

Zander and Regen are under common control.

As of March 31, 2024, $0 of the principal amount of the Note remains outstanding and all accrued interest has been paid.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

XML 25 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY

6 Months Ended

Mar. 31, 2024

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 7. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of March 31, 2024:

Common stock, $ 0.0001 par value; 5,800,000,000 shares authorized: 4,114,622 shares issued and outstanding.

Series AA Preferred Stock

Series A Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY

6 Months Ended

Mar. 31, 2024

Investment Securities Related Party

INVESTMENT SECURITIES, RELATED PARTY

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

Dividend income
Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40,000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders		708,916
Fair Value Per Share	$	0.0155

The abovementioned constitute the Company’s sole related party investment securities as of March 31, 2024.

As of March 31, 2024:

	Comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024
$	5,741	$	6,496	$	755	$	(0	)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024
$	13,124	$	11,238	$	(1,866	)	$	(0	)

XML 27 R16.htm IDEA: XBRL DOCUMENT

STOCK TRANSACTIONS

6 Months Ended

Mar. 31, 2024

Stock Transactions

STOCK TRANSACTIONS

NOTE 9. STOCK TRANSACTIONS

On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638.

On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $44,297.

On February 2, 2024 the Company issued 40,229 common shares for cash consideration of $19,614.

On February 21, 2024 the Company issued 52,569 common shares for cash consideration of $32,362.

On March 6, 2024 the Company issued 44,503 common shares for cash consideration of $25,282.

On March 20, 2024 the Company issued 49,230 common shares for cash consideration of $26,781.

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10. SUBSEQUENT EVENTS

On April 3, 2024 the Company issued 52,763 common shares for cash consideration of $25,326.

XML 29 R18.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

BASIS OF ACCOUNTING

A. BASIS OF ACCOUNTING

PRINCIPLES OF CONSOLIDATION

B. PRINCIPLES OF CONSOLIDATION

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(1.70) – (4.08) Yrs
Expected Volatility	932.98	%
Expected Dividends

INCOME TAXES

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

BASIC EARNINGS (LOSS) PER SHARE

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

ADVERTISING

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2023 and March 31, 2024.

NOTES RECEIVABLE

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

REVENUE RECOGNITION

L. REVENUE RECOGNITION

INTEREST RECEIVABLE

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule of Derivative liability

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(1.70) – (4.08) Yrs
Expected Volatility	932.98	%
Expected Dividends

XML 31 R20.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

6 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Notes payable related party

Notes payable related party
	As of March 31, 2024
David Koos	$	710
Total:	$	710

Schedule of non related party

Schedule of non related party
Bostonia Partners, Inc	$	100.000
Total:	$	100,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Tables)

6 Months Ended

Mar. 31, 2024

Investment Securities Related Party

Dividend income

Dividend income
Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40,000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders		708,916
Fair Value Per Share	$	0.0155

Comprehensive income

	Comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024
$	5,741	$	6,496	$	755	$	(0	)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024
$	13,124	$	11,238	$	(1,866	)	$	(0	)

XML 33 R22.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	6 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	5.39%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	932.98%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	1 year 8 months 12 days
Maximum [Member]
Property, Plant and Equipment [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	4 years 29 days

XML 34 R23.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	6 Months Ended
	Mar. 31, 2024 USD ($)
Accounting Policies [Abstract]
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	100.00%
Advertising Expense	$ 0

XML 35 R24.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)		3 Months Ended		128 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Sep. 12, 2023	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss since inception				$ 20,221,096
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price	$ 1.25
Common Stock [Member] \| Coventry Enterprises L L C [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares Issued, Price Per Share	$ 1.50
Equity Line Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Repurchased During Period, Value	$ 10,000,000
[custom:CommonStocksParOrStatedValuePerShare-0]	$ 0.0001
Equity Line Agreement [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues	125,000	364,057	244,199
Sale of Stock, Number of Shares Issued in Transaction	1,126,954
Stock Issued During Period, Value, New Issues		$ 187,937	$ 212,296

XML 36 R25.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - Related Party [Member]	Mar. 31, 2024 USD ($)
Short-Term Debt [Line Items]
Notes Payable	$ 710
David Koos [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 710

XML 37 R26.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details 1) - Nonrelated Party [Member]	Mar. 31, 2024 USD ($)
Short-Term Debt [Line Items]
Notes Payable	$ 100,000
Bostonia [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 100.000

XML 38 R27.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)		6 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 12, 2023	Mar. 31, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Notes Payable, Noncurrent		$ 143,685	$ 149,614
Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument Issued Principal	$ 175,000
[custom:OriginalIssueDiscount]	26,250
[custom:GuaranteedInterest]	26,250
[custom:GuaranteedInterestOnPrincipalAmountDue]	$ 28,750
Notes Payable, Noncurrent		160,000
David Koos [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross		$ 710
Debt Instrument, Interest Rate During Period		15.00%
Bostonia [Member] \| Due And Payable March 102024 [Member]
Debt Instrument [Line Items]
Long-Term Debt, Gross		$ 48,500
Debt Instrument, Interest Rate During Period		10.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative)	Mar. 31, 2024 USD ($)
Convertible Note; March 8, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	$ 100,000
Cash issued for convertible note	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	8.00%
Notes Payable, Current	$ 100,000
Convertible Note; April 6, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000
Cash issued for convertible note	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	800.00%
Notes Payable, Current	$ 50,000
October 312016 [Member]
Short-Term Debt [Line Items]
Notes Payable, Current	50,000
Convertible Note; May 5, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	200,000
Cash issued for convertible note	$ 200,000
Debt Instrument, Interest Rate, Effective Percentage	1000.00%
Notes Payable, Current	$ 200,000
Derivative Liability, Current	800,000
Convertible Note; December 20, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	100,000
Cash issued for convertible note	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	1000.00%
Notes Payable, Current	$ 100,000
Derivative Liability, Current	400,000
Convertible Note; October 3, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000
Cash issued for convertible note	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	1000.00%
Notes Payable, Current	$ 50,000
Derivative Liability, Current	$ 200,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative)	Mar. 31, 2024 USD ($)
Related Party [Member]
Short-Term Debt [Line Items]
Notes Payable, Related Parties, Current	$ 710
Convertible Note; September 30, 2018
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	350,000
Notes Payable, Related Parties, Current	0
David Koos [Member]
Short-Term Debt [Line Items]
Long-Term Debt, Gross	710
David Koos [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Notes Payable, Related Parties, Current	$ 710

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Mar. 31, 2024	Sep. 30, 2023
Class of Stock [Line Items]
Common Stock, Shares Authorized	5,800,000,000	5,800,000,000
Common Stock, Shares, Outstanding	4,114,622	3,506,366
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	800,000,000	800,000,000
Series AA Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	600,000	600,000
Preferred Stock, Shares Outstanding	34	34
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	739,000,000	739,000,000
Preferred Stock, Shares Outstanding	409,551	409,551
Series M Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	60,000,000	60,000,000
Preferred Stock, Shares Outstanding	29,338	29,338
Series N C [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	20,000	20,000
Preferred Stock, Shares Outstanding	15,007	15,007

XML 42 R31.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Prepaid Expense, Current	$ 200	$ 0
Accounts Payable, Current	29,798	$ 29,674
Series M Preferred Stock [Member] \| Zander Therapeutics
Fair Value of Intellectual Property	300,000
Prepaid Expense, Current	65,661
Due from Employees	0
Receivables, Net, Current	40,000
Accrued Investment Income Receivable	35,000
Investments	258,255
Convertible Note Receivable	10,000
Accounts Payable, Current	30,563
Notes Payables	400,000
Accrued Expenses, Related Party	162,011
Notes Payable, Related Parties, Current	0
Accrued Liabilities, Current	647,072
Enterprise Value	1,948,562
Debt, Current	(1,239,646)
Portion of Enterprise Value attributable to Shareholders	$ 708,916
Fair Value per share	$ 0.0155

XML 43 R32.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Details 1) - Zander Therapeutics	6 Months Ended
	Mar. 31, 2024 USD ($)
Common Stock [Member]
Investment Securities, Basis	$ 5,741
Investment Securities, Fair Value	6,496
Investment Securities, Total Unrealized Gain	755
Investment Securities, net Unrealized Gain or (Loss) realized	(0)
Series M Preferred Stock [Member]
Investment Securities, Basis	13,124
Investment Securities, Fair Value	11,238
Investment Securities, Total Unrealized Gain	(1,866)
Investment Securities, net Unrealized Gain or (Loss) realized	$ (0)

XML 44 R33.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) - Zander Therapeutics - USD ($)		1 Months Ended	6 Months Ended
	Jun. 11, 2018	Nov. 29, 2018	Mar. 31, 2024
Number Of Shares Issued For Property Dividend	470,588		470,588
Series M Preferred Stock [Member]
Number Of Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest		725,000	725,000
Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest Value		$ 13,124

XML 45 R34.htm IDEA: XBRL DOCUMENT

STOCK TRANSACTIONS (Details Narrative) - USD ($)	Apr. 03, 2024	Mar. 31, 2024	Mar. 20, 2024	Mar. 06, 2024	Feb. 21, 2024	Feb. 02, 2024	Jan. 10, 2024	Jan. 03, 2024	Sep. 30, 2023
Common Stock, Value, Issued	$ 25,326	$ 412	$ 26,781	$ 25,282	$ 32,362	$ 19,614	$ 44,297	$ 39,638	$ 352
Common Stock [Member]
Common Stock, Shares, Issued	52,763		49,230	44,503	52,569	40,229	82,643	94,883

XML 46 R35.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 03, 2024	Mar. 31, 2024	Mar. 20, 2024	Mar. 06, 2024	Feb. 21, 2024	Feb. 02, 2024	Jan. 10, 2024	Jan. 03, 2024	Sep. 30, 2023
Common Stock, Value, Issued	$ 25,326	$ 412	$ 26,781	$ 25,282	$ 32,362	$ 19,614	$ 44,297	$ 39,638	$ 352
Common Stock [Member]
Common Stock, Shares, Issued	52,763		49,230	44,503	52,569	40,229	82,643	94,883

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 149 219 1 false 33 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://regenbiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://regenbiopharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://regenbiopharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://regenbiopharma.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfCashFlows Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://regenbiopharma.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 9 false false R10.htm 00000010 - Disclosure - GOING CONCERN Sheet http://regenbiopharma.com/role/GoingConcern GOING CONCERN Notes 10 false false R11.htm 00000011 - Disclosure - NOTES PAYABLE Notes http://regenbiopharma.com/role/NotesPayable NOTES PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://regenbiopharma.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://regenbiopharma.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://regenbiopharma.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParty INVESTMENT SECURITIES, RELATED PARTY Notes 15 false false R16.htm 00000016 - Disclosure - STOCK TRANSACTIONS Sheet http://regenbiopharma.com/role/StockTransactions STOCK TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://regenbiopharma.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - NOTES PAYABLE (Tables) Notes http://regenbiopharma.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://regenbiopharma.com/role/NotesPayable 20 false false R21.htm 00000021 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Tables) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables INVESTMENT SECURITIES, RELATED PARTY (Tables) Tables http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParty 21 false false R22.htm 00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://regenbiopharma.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://regenbiopharma.com/role/GoingConcern 24 false false R25.htm 00000025 - Disclosure - NOTES PAYABLE (Details) Notes http://regenbiopharma.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://regenbiopharma.com/role/NotesPayableTables 25 false false R26.htm 00000026 - Disclosure - NOTES PAYABLE (Details 1) Notes http://regenbiopharma.com/role/NotesPayableDetails1 NOTES PAYABLE (Details 1) Details http://regenbiopharma.com/role/NotesPayableTables 26 false false R27.htm 00000027 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://regenbiopharma.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://regenbiopharma.com/role/NotesPayableTables 27 false false R28.htm 00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://regenbiopharma.com/role/ConvertibleNotesPayable 28 false false R29.htm 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://regenbiopharma.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://regenbiopharma.com/role/StockholdersEquity 30 false false R31.htm 00000031 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails INVESTMENT SECURITIES, RELATED PARTY (Details) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables 31 false false R32.htm 00000032 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1 INVESTMENT SECURITIES, RELATED PARTY (Details 1) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables 32 false false R33.htm 00000033 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables 33 false false R34.htm 00000034 - Disclosure - STOCK TRANSACTIONS (Details Narrative) Sheet http://regenbiopharma.com/role/StockTransactionsDetailsNarrative STOCK TRANSACTIONS (Details Narrative) Details http://regenbiopharma.com/role/StockTransactions 34 false false R35.htm 00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://regenbiopharma.com/role/SubsequentEvents 35 false false All Reports Book All Reports rgbp-20240331.xsd rgbp-20240331_cal.xml rgbp-20240331_def.xml rgbp-20240331_lab.xml rgbp-20240331_pre.xml rgbp033124form10q.htm http://fasb.org/us-gaap-sup/2022q3 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rgbp033124form10q.htm": { "nsprefix": "RGBP", "nsuri": "http://regenbiopharma.com/20240331", "dts": { "schema": { "local": [ "rgbp-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "calculationLink": { "local": [ "rgbp-20240331_cal.xml" ] }, "definitionLink": { "local": [ "rgbp-20240331_def.xml" ] }, "labelLink": { "local": [ "rgbp-20240331_lab.xml" ] }, "presentationLink": { "local": [ "rgbp-20240331_pre.xml" ] }, "inline": { "local": [ "rgbp033124form10q.htm" ] } }, "keyStandard": 136, "keyCustom": 83, "axisStandard": 7, "axisCustom": 1, "memberStandard": 6, "memberCustom": 23, "hidden": { "total": 176, "http://xbrl.sec.gov/dei/2022": 5, "http://regenbiopharma.com/20240331": 135, "http://fasb.org/us-gaap/2022": 36 }, "contextCount": 149, "entityCount": 1, "segmentCount": 33, "elementCount": 339, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 368, "http://xbrl.sec.gov/dei/2022": 27, "http://fasb.org/us-gaap-sup/2022q3": 1 }, "report": { "R1": { "role": "http://regenbiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://regenbiopharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://regenbiopharma.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit", "longName": "00000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-09-30_custom_PreferredStockSeriesAMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-09-30_custom_PreferredStockSeriesAMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical", "longName": "00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statement of Shareholders' Equity (Deficit) (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "RGBP:SharesIssuedForCashShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "RGBP:SharesIssuedForCashShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://regenbiopharma.com/role/StatementOfCashFlows", "longName": "00000007 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-012023-03-31", "name": "RGBP:PreferredStockIssuedAsCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "unique": true } }, "R8": { "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://regenbiopharma.com/role/RecentAccountingPronouncements", "longName": "00000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://regenbiopharma.com/role/GoingConcern", "longName": "00000010 - Disclosure - GOING CONCERN", "shortName": "GOING CONCERN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://regenbiopharma.com/role/NotesPayable", "longName": "00000011 - Disclosure - NOTES PAYABLE", "shortName": "NOTES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://regenbiopharma.com/role/ConvertibleNotesPayable", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE", "shortName": "CONVERTIBLE NOTES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "RGBP:ConvertibleNotesPayableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "RGBP:ConvertibleNotesPayableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://regenbiopharma.com/role/RelatedPartyTransactions", "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://regenbiopharma.com/role/StockholdersEquity", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParty", "longName": "00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY", "shortName": "INVESTMENT SECURITIES, RELATED PARTY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://regenbiopharma.com/role/StockTransactions", "longName": "00000016 - Disclosure - STOCK TRANSACTIONS", "shortName": "STOCK TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "RGBP:StockTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "RGBP:StockTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://regenbiopharma.com/role/SubsequentEvents", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000018 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://regenbiopharma.com/role/NotesPayableTables", "longName": "00000020 - Disclosure - NOTES PAYABLE (Tables)", "shortName": "NOTES PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables", "longName": "00000021 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Tables)", "shortName": "INVESTMENT SECURITIES, RELATED PARTY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-01to2024-03-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "longName": "00000024 - Disclosure - GOING CONCERN (Details Narrative)", "shortName": "GOING CONCERN (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2012-07-242023-03-31", "name": "RGBP:NetIncomeLossSinceInception", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2012-07-242023-03-31", "name": "RGBP:NetIncomeLossSinceInception", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://regenbiopharma.com/role/NotesPayableDetails", "longName": "00000025 - Disclosure - NOTES PAYABLE (Details)", "shortName": "NOTES PAYABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-03-31_custom_RelatedPartyMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://regenbiopharma.com/role/NotesPayableDetails1", "longName": "00000026 - Disclosure - NOTES PAYABLE (Details 1)", "shortName": "NOTES PAYABLE (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2024-03-31_custom_NonrelatedPartyMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_custom_NonrelatedPartyMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "longName": "00000027 - Disclosure - NOTES PAYABLE (Details Narrative)", "shortName": "NOTES PAYABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:LongTermNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-09-112023-09-12_custom_UnsecuredPromissoryNoteMember", "name": "us-gaap-supplement:DebtInstrumentIssuedPrincipal", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "unique": true } }, "R28": { "role": "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "longName": "00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-03-31_custom_March82016Member", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "RGBP:ConvertibleNotesPayableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_custom_March82016Member", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "RGBP:ConvertibleNotesPayableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-03-31_custom_RelatedPartyMember", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_custom_September302018Member", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "unique": true } }, "R30": { "role": "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative", "longName": "00000030 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "longName": "00000031 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details)", "shortName": "INVESTMENT SECURITIES, RELATED PARTY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember", "name": "RGBP:FairValueOfIntellectualProperty", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "unique": true } }, "R32": { "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "longName": "00000032 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1)", "shortName": "INVESTMENT SECURITIES, RELATED PARTY (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember", "name": "RGBP:InvestmentSecuritiesBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember", "name": "RGBP:InvestmentSecuritiesBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "longName": "00000033 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details Narrative)", "shortName": "INVESTMENT SECURITIES, RELATED PARTY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2018-06-012018-06-11_custom_ZanderTherapeuticsMember", "name": "RGBP:NumberOfSharesIssuedForPropertyDividend", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2018-06-012018-06-11_custom_ZanderTherapeuticsMember", "name": "RGBP:NumberOfSharesIssuedForPropertyDividend", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "longName": "00000034 - Disclosure - STOCK TRANSACTIONS (Details Narrative)", "shortName": "STOCK TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-04-03", "name": "us-gaap:CommonStockValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative", "longName": "00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2024-04-03", "name": "us-gaap:CommonStockValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "rgbp033124form10q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Payroll", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "verboseLabel": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r343" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Related Party", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r172", "r173" ] }, "RGBP_AccruedExpensesRelated": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "AccruedExpensesRelated", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses, Related Party" } } }, "auth_ref": [] }, "us-gaap_AccruedInvestmentIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedInvestmentIncomeReceivable", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Investment Income Receivable", "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments." } } }, "auth_ref": [ "r73", "r88", "r369" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Interest", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued payroll taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r10", "r343" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r247", "r248", "r249", "r377", "r378", "r379", "r397" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net Income to net cash" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "ADVERTISING", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r250" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r251" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentDescription", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Interest expense attributable to amortization of Discount", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r217", "r289", "r337", "r338", "r372" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AnnualInformationForm", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r359" ] }, "RGBP_April62016Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "April62016Member", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note; April 6, 2016" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Assets", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r74", "r83", "r104", "r125", "r160", "r163", "r167", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r264", "r268", "r278", "r343", "r389", "r390", "r399" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsAbstract", "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r101", "r110", "r125", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r264", "r268", "r278", "r343", "r389", "r390", "r399" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsCurrentAbstract", "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r359" ] }, "RGBP_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1" ], "lang": { "en-us": { "role": { "label": "Investment Securities, Total Unrealized Gain" } } }, "auth_ref": [] }, "us-gaap_BankOverdrafts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BankOverdrafts", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Bank Overdraft", "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing." } } }, "auth_ref": [ "r19", "r45" ] }, "RGBP_BasicAndFullyDilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "BasicAndFullyDilutedEarningsLossPerShare", "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "BASIS OF ACCOUNTING", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "RGBP_BostoniaMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "BostoniaMember", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bostonia [Member]" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Cash", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r320", "r321", "r343", "r366" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at Beginning of Period", "periodEndLabel": "Cash at End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r36", "r37" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r68" ] }, "RGBP_CashIssuedForConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CashIssuedForConvertibleNote", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash issued for convertible note" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfStockDomain", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r106", "r107", "r108", "r125", "r148", "r149", "r152", "r153", "r155", "r156", "r176", "r186", "r188", "r189", "r190", "r193", "r194", "r224", "r225", "r228", "r232", "r239", "r278", "r324", "r365", "r374", "r380" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfStockLineItems", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "RGBP_CommonSharesIssuedForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CommonSharesIssuedForDebt", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "RGBP_PreferredSharesIssuedForInterests", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common shares Issued for Debt" } } }, "auth_ref": [] }, "RGBP_CommonSharesIssuedForInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CommonSharesIssuedForInterest", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "11/11/2022", "label": "Common Shares Issued For Interest" } } }, "auth_ref": [] }, "RGBP_CommonSharesIssuedForInterestShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CommonSharesIssuedForInterestShares", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Shares Issued For Interest, Shares" } } }, "auth_ref": [] }, "RGBP_CommonSharesIssuedForInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CommonSharesIssuedForInterests", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "RGBP_PreferredSharesIssuedForInterests", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common shares Issued for Interest" } } }, "auth_ref": [] }, "RGBP_CommonSharesIssuedPursuantToRoundUpProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CommonSharesIssuedPursuantToRoundUpProvision", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "3/13/2023" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockMember", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r377", "r378", "r397" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r9" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r9" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesIssued", "presentation": [ "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r9" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r53" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and\u00a04,114,622\u00a0issued and outstanding as of March\u00a031, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023.", "verboseLabel": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r9", "r343" ] }, "RGBP_CommonStocksParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CommonStocksParOrStatedValuePerShare", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:CommonStocksParOrStatedValuePerShare-0]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "PRINCIPLES OF CONSOLIDATION", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r65", "r328" ] }, "RGBP_ContributedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ContributedCapitalMember", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Contributed Capital [Member]" } } }, "auth_ref": [] }, "RGBP_ConvertibleNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ConvertibleNoteReceivable", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Note Receivable" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ConvertibleNotesPayable", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Less\u00a0unamortized discount", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r6", "r76", "r84", "r92" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r19" ] }, "RGBP_ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable, Related Parties Less\u00a0unamortized discount" } } }, "auth_ref": [] }, "RGBP_ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Convertible Notes Payable, Related Parties Less\u00a0unamortized discount", "label": "ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent" } } }, "auth_ref": [] }, "RGBP_ConvertibleNotesPayableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ConvertibleNotesPayableTextBlock", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total Costs and Expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "COST AND EXPENSES" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CountryRegion", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "RGBP_CoventryEnterprisesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "CoventryEnterprisesLLCMember", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Coventry Enterprises L L C [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "RGBP_DavidKoosMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DavidKoosMember", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "David Koos [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtCurrent", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt, Current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r105" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://regenbiopharma.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r49", "r123", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r211", "r218", "r219", "r221" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentAxis", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r4", "r5", "r6", "r75", "r76", "r81", "r126", "r195", "r196", "r197", "r198", "r199", "r201", "r207", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r290", "r334", "r335", "r336", "r337", "r338", "r375" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r6", "r76", "r81", "r222" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r21", "r70", "r214" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r21", "r70", "r223", "r290" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-sup/2022q3", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Issued Principal" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentLineItems", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r126", "r195", "r196", "r197", "r198", "r199", "r201", "r207", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r290", "r334", "r335", "r336", "r337", "r338", "r375" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentTable", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r54", "r57", "r58", "r59", "r69", "r70", "r72", "r80", "r126", "r195", "r196", "r197", "r198", "r199", "r201", "r207", "r208", "r209", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r220", "r290", "r334", "r335", "r336", "r337", "r338", "r375" ] }, "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1" ], "lang": { "en-us": { "role": { "label": "Investment Securities, Fair Value", "documentation": "Cost of investment in debt investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain ( Loss) on sale of Investment Securities", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [] }, "RGBP_Dec2017Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "Dec2017Member", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note; December 20, 2017" } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Derivative Income (Expense)", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r396" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r111", "r112", "r277", "r327" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r111" ] }, "RGBP_DisclosureConvertibleNotesPayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DisclosureConvertibleNotesPayableAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes Payable" } } }, "auth_ref": [] }, "RGBP_DisclosureInvestmentSecuritiesRelatedPartyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DisclosureInvestmentSecuritiesRelatedPartyAbstract", "lang": { "en-us": { "role": { "label": "Investment Securities Related Party" } } }, "auth_ref": [] }, "RGBP_DisclosureStockTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DisclosureStockTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Stock Transactions" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentAccountingStandard", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r358" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentAnnualReport", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r356", "r358", "r359" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodStartDate", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentQuarterlyReport", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r357" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentRegistrationStatement", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r345" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r358" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentShellCompanyReport", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r358" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentTransitionReport", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r360" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r348" ] }, "RGBP_DueAndPayableMarch102024Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DueAndPayableMarch102024Member", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due And Payable March 102024 [Member]" } } }, "auth_ref": [] }, "RGBP_DueFromEmployeeRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DueFromEmployeeRelatedParty", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Due from Employees" } } }, "auth_ref": [] }, "RGBP_DueToInvestor": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "DueToInvestor", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Due to Investor" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "BASIC EARNINGS (LOSS) PER SHARE", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r40", "r41" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r393", "r394" ] }, "RGBP_EnterpriseValue": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "EnterpriseValue", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Enterprise Value" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine3", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCountry", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r351" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r347" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityDomain", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r347" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r364" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFilerCategory", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r347" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r361" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityPrimarySicNumber", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r359" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r347" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityShellCompany", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r347" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntitySmallBusiness", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r347" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r347" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityVoluntaryFilers", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r362" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquityComponentDomain", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r53", "r97", "r116", "r117", "r118", "r127", "r128", "r129", "r133", "r140", "r142", "r154", "r177", "r240", "r247", "r248", "r249", "r258", "r259", "r272", "r282", "r283", "r284", "r285", "r286", "r287", "r294", "r312", "r313", "r314" ] }, "RGBP_EquityLineAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "EquityLineAgreementMember", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Line Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1" ], "lang": { "en-us": { "role": { "label": "Investment Securities, net Unrealized Gain or (Loss) realized", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r310", "r385" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Extension", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "RGBP_FairValueOfIntellectualProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "FairValueOfIntellectualProperty", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value of Intellectual Property" } } }, "auth_ref": [] }, "RGBP_FairValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "FairValuePerShare", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value per share" } } }, "auth_ref": [] }, "RGBP_GainLossOnForgivenessOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "GainLossOnForgivenessOfDebt", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) Loss\u00a0on forgiveness of Debt", "label": "GainLossOnForgivenessOfDebt" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on\u00a0Extinguishment Convertible Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r34", "r47", "r48" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r28" ] }, "RGBP_GuaranteedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "GuaranteedInterest", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:GuaranteedInterest]" } } }, "auth_ref": [] }, "RGBP_GuaranteedInterestOnPrincipalAmountDue": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "GuaranteedInterestOnPrincipalAmountDue", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:GuaranteedInterestOnPrincipalAmountDue]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r115", "r252", "r253", "r254", "r255", "r256", "r257" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Increase) Decrease in Accounts Receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in accrued Expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r33" ] }, "RGBP_IncreaseDecreaseInCommonStockIssuedForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "IncreaseDecreaseInCommonStockIssuedForCash", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Common Stock issued for cash" } } }, "auth_ref": [] }, "RGBP_IncreaseDecreaseInContributedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "IncreaseDecreaseInContributedCapital", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase(Decrease) in Contributed Capital" } } }, "auth_ref": [] }, "RGBP_IncreaseDecreaseInConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "IncreaseDecreaseInConvertibleNotesPayable", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Convertible Notes Payable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInDerivativeLiabilities", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase ( Decrease)\u00a0in Derivative Expense", "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInNotesPayableCurrent", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in\u00a0Notes Payable", "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Increase) Decrease in Prepaid Expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInUnearnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInUnearnedPremiums", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase ( Decrease) in Unearned Income", "documentation": "Amount of increase (decrease) unearned premiums written. Excludes portion of unearned premiums amortized into income." } } }, "auth_ref": [ "r33" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest Expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r71", "r79", "r119", "r159", "r288" ] }, "RGBP_InterestExpenseAttributableToAmortizationOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "InterestExpenseAttributableToAmortizationOfDiscount", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense attributable to Amortization of Discount" } } }, "auth_ref": [] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InterestPaid", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "RGBP_PreferredSharesIssuedForInterests", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Paid for Interest", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": [ "r373" ] }, "RGBP_InterestReceivablePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "InterestReceivablePolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "INTEREST RECEIVABLE" } } }, "auth_ref": [] }, "RGBP_InvestmentSecuritiesBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "InvestmentSecuritiesBasis", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1" ], "lang": { "en-us": { "role": { "label": "Investment Securities, Basis" } } }, "auth_ref": [] }, "RGBP_InvestmentSecuritiesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "InvestmentSecuritiesRelatedParty", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investment Securities, Related Party" } } }, "auth_ref": [] }, "RGBP_InvestmentSecuritiesRelatedPartyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "InvestmentSecuritiesRelatedPartyTextBlock", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParty" ], "lang": { "en-us": { "role": { "label": "INVESTMENT SECURITIES, RELATED PARTY" } } }, "auth_ref": [] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Investments", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r90" ] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeaseAndRentalExpense", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Rent", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LegalEntityAxis", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r125", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r265", "r268", "r269", "r278", "r331", "r389", "r399", "r400" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r14", "r77", "r87", "r343", "r376", "r386", "r398" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r102", "r125", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r265", "r268", "r269", "r278", "r343", "r389", "r399", "r400" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Long Term Liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r2", "r3", "r6", "r7", "r125", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r265", "r268", "r269", "r278", "r389", "r399", "r400" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long Term Liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes Payable", "label": "Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r22" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r22" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r46" ] }, "RGBP_March82016Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "March82016Member", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note; March 8, 2016" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MaximumMember", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r182", "r183", "r184", "r185", "r242", "r304", "r311", "r322", "r323", "r339", "r340", "r344", "r391", "r401", "r402", "r403", "r404", "r405", "r406" ] }, "RGBP_May52017Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "May52017Member", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note; May 5, 2017" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MinimumMember", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r182", "r183", "r184", "r185", "r242", "r304", "r311", "r322", "r323", "r339", "r340", "r344", "r391", "r401", "r402", "r403", "r404", "r405", "r406" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r122" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r31", "r32", "r35" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows", "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME (LOSS)", "label": "Net Income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r26", "r35", "r78", "r91", "r100", "r113", "r114", "r118", "r125", "r132", "r136", "r137", "r138", "r139", "r141", "r142", "r150", "r160", "r162", "r166", "r168", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r273", "r278", "r332", "r389" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME (LOSS) attributable to common shareholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r136", "r137", "r138", "r139", "r146", "r147", "r151", "r153", "r160", "r162", "r166", "r168", "r332" ] }, "RGBP_NetIncomeLossSinceInception": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "NetIncomeLossSinceInception", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net loss since inception" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://regenbiopharma.com/role/RecentAccountingPronouncements" ], "lang": { "en-us": { "role": { "label": "RECENT ACCOUNTING PRONOUNCEMENTS", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r99", "r130", "r131", "r134", "r135", "r143", "r144", "r145", "r174", "r175", "r178", "r179", "r260", "r261", "r262", "r271", "r274", "r275", "r276", "r279", "r280", "r281", "r291", "r292", "r293", "r295", "r306", "r307", "r308", "r315", "r316", "r317", "r318", "r319" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NoTradingSymbolFlag", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "RGBP_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "NonrelatedPartyMember", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NotesAndLoansPayable", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r6", "r76", "r85" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payables", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r6", "r76", "r85" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes Payable", "label": "Notes Payable, Current", "terseLabel": "Notes Payable, Related Parties, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r17" ] }, "RGBP_NotesPayableRelatedPartyClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "NotesPayableRelatedPartyClassifiedCurrent", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Related Parties, Current" } } }, "auth_ref": [] }, "RGBP_NotesReceivableRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "NotesReceivableRelatedPartyCurrent", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Note Receivable, Related Party" } } }, "auth_ref": [] }, "RGBP_NumberOfSharesIssuedForPropertyDividend": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "NumberOfSharesIssuedForPropertyDividend", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Issued For Property Dividend" } } }, "auth_ref": [] }, "RGBP_NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest" } } }, "auth_ref": [] }, "RGBP_Oct0317Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "Oct0317Member", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note; October 3, 2017" } } }, "auth_ref": [] }, "RGBP_October312016Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "October312016Member", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "October 312016 [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "OPERATING INCOME (LOSS)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r160", "r162", "r166", "r168", "r332" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r38", "r39", "r42", "r67" ] }, "RGBP_OriginalIssueDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "OriginalIssueDiscount", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "[custom:OriginalIssueDiscount]" } } }, "auth_ref": [] }, "RGBP_OtherAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "OtherAccruedExpenses", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_OtherAdditionalCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAdditionalCapital", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contributed Capital", "documentation": "Amount of additional paid-in capital (APIC) classified as other." } } }, "auth_ref": [ "r24", "r30" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Other Assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r73", "r82", "r103" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OTHER INCOME & (EXPENSES)" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL OTHER INCOME (EXPENSE)", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r35" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r358" ] }, "RGBP_PortionOfEnterpriseValueAttributableToShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PortionOfEnterpriseValueAttributableToShareholders", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Portion of Enterprise Value attributable to Shareholders" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r352" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r353" ] }, "RGBP_PreferredShareIssuedForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredShareIssuedForDebt", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "RGBP_PreferredSharesIssuedForInterests", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Preferred Shares Issued for Debt" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForDebt", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "11/11/2022" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForDebtShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForDebtShares", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Shares Issued for Debt, Shares" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForInterest", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "11/11/2022", "label": "Preferred Shares Issued for Interest" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForInterestShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForInterestShares", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Shares Issued for Interest, Shares" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForInterests", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Preferred Shares issued for Interest" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForNonemployeeServices": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForNonemployeeServices", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "10/25/2022" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForNonemployeeServices1": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForNonemployeeServices1", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "12/5/2022" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForNonemployeeServicesShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForNonemployeeServicesShares", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Shares Issued for Nonemployee Services, Shares" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedForNonemployeeServicesShares1": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedForNonemployeeServicesShares1", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "PreferredSharesIssuedForNonemployeeServicesShares1" } } }, "auth_ref": [] }, "RGBP_PreferredSharesIssuedPursuantToRoundUpProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredSharesIssuedPursuantToRoundUpProvision", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "3/13/2023", "label": "PreferredSharesIssuedPursuantToRoundUpProvision" } } }, "auth_ref": [] }, "RGBP_PreferredStockIssuedAsCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredStockIssuedAsCompensation", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Preferred Stock issued as compensation", "label": "PreferredStockIssuedAsCompensation" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r8", "r224" ] }, "RGBP_PreferredStockSeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "PreferredStockSeriesAMember", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Series A [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, 0.0001 par value, 800,000,000 authorized as of March 31, 2024 and September\u00a030, 2023 respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r8", "r343" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses", "verboseLabel": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r109", "r180", "r181", "r325" ] }, "us-gaap_PrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PrepaidRent", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Rent", "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r326", "r333", "r387" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Consulting and Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r94", "r95" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r100", "r113", "r114", "r121", "r125", "r132", "r141", "r142", "r160", "r162", "r166", "r168", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r263", "r266", "r267", "r273", "r278", "r309", "r332", "r341", "r342", "r370", "r389" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RangeAxis", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r182", "r183", "r184", "r185", "r241", "r242", "r244", "r245", "r246", "r303", "r304", "r311", "r322", "r323", "r339", "r340", "r344", "r388", "r391", "r402", "r403", "r404", "r405", "r406" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RangeMember", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "auth_ref": [ "r182", "r183", "r184", "r185", "r241", "r242", "r244", "r245", "r246", "r303", "r304", "r311", "r322", "r323", "r339", "r340", "r344", "r388", "r391", "r402", "r403", "r404", "r405", "r406" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r89", "r93", "r343" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "NOTES RECEIVABLE", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r381", "r382", "r383", "r384" ] }, "RGBP_RelatedAndNonrelatedPartyStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "RelatedAndNonrelatedPartyStatusAxis", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related And Nonrelated Party Status [Axis]", "verboseLabel": "RelatedAndNonrelatedPartyStatusAxis [Axis]" } } }, "auth_ref": [] }, "RGBP_RelatedAndNonrelatedPartyStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "RelatedAndNonrelatedPartyStatusDomain", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "auth_ref": [] }, "RGBP_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "RelatedPartyMember", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://regenbiopharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r300" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r62", "r96", "r407" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Deficit)", "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit." } } }, "auth_ref": [ "r11", "r60", "r86", "r315", "r319", "r343" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RetainedEarningsMember", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit." } } }, "auth_ref": [ "r97", "r127", "r128", "r129", "r133", "r140", "r142", "r177", "r247", "r248", "r249", "r258", "r259", "r272", "r312", "r314" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "REVENUE RECOGNITION", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r329", "r330" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Revenues", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "RGBP_TotalRevenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r120", "r125", "r157", "r158", "r161", "r164", "r165", "r169", "r170", "r171", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r278", "r309", "r389" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenuesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "REVENUES" } } }, "auth_ref": [] }, "RGBP_RevenuesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "RevenuesRelatedParty", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "RGBP_TotalRevenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues, Related Party" } } }, "auth_ref": [] }, "RGBP_ReverseStockSplitShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ReverseStockSplitShares", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "March 6,2023 reverse stock split" } } }, "auth_ref": [] }, "RGBP_ReverseStockSplitShares1": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ReverseStockSplitShares1", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "March 6,2023 reverse stock split", "label": "ReverseStockSplitShares1" } } }, "auth_ref": [] }, "RGBP_ReverseStockSplitValue": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ReverseStockSplitValue", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "" } } }, "auth_ref": [] }, "RGBP_ReverseStockSplitValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ReverseStockSplitValue1", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "", "label": "ReverseStockSplitValue1" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r395" ] }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://regenbiopharma.com/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Notes payable related party", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative liability", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyTables" ], "lang": { "en-us": { "role": { "label": "Dividend income", "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://regenbiopharma.com/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of non related party", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r50", "r51", "r52", "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r106", "r107", "r108", "r155", "r224", "r225", "r226", "r228", "r232", "r237", "r239", "r339", "r365", "r374" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r346" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12gTitle", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r350" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r349" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityReportingObligation", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r354" ] }, "RGBP_September302018Member": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "September302018Member", "presentation": [ "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note; September 30, 2018" } } }, "auth_ref": [] }, "RGBP_SeriesAAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SeriesAAPreferredStockMember", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series AA Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r367", "r368", "r392" ] }, "RGBP_SeriesMMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SeriesMMember", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series M Preferred Stock [Member]" } } }, "auth_ref": [] }, "RGBP_SeriesMPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SeriesMPreferredStockMember", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Series M Preferred Stock [Member]", "label": "SeriesMPreferredStockMember" } } }, "auth_ref": [] }, "RGBP_SeriesNCMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SeriesNCMember", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series N C [Member]" } } }, "auth_ref": [] }, "RGBP_SeriesNCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SeriesNCPreferredStockMember", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series N C Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r244" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r246" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharePrice", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r243" ] }, "RGBP_SharesIssuedForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "10/13/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash10": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash10", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "2/21/2024" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash11": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash11", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "3/6/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash12": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash12", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "3/20/2024" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash2", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "10/27/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash3": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash3", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "11/10/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash4": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash4", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "11/27/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash5": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash5", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "12/11/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash6": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash6", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "12/20/2023" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash7": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash7", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "1/3/2024" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash8": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash8", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "1/10/2024" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCash9": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCash9", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "2/2/2024" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares10": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares10", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares10]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares11": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares11", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares11]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares12": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares12", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares12]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares2": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares2", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares2]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares3": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares3", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares3]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares4": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares4", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares4]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares5": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares5", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares5]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares6": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares6", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares6]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares7": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares7", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares7]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares8": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares8", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares8]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedForCashShares9": { "xbrltype": "sharesItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedForCashShares9", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "[custom:SharesIssuedForCashShares9]" } } }, "auth_ref": [] }, "RGBP_SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest Value" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharesOutstanding", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShortTermDebtLineItems", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r355" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementClassOfStockAxis", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r106", "r107", "r108", "r125", "r148", "r149", "r152", "r153", "r155", "r156", "r176", "r186", "r188", "r189", "r190", "r193", "r194", "r224", "r225", "r228", "r232", "r239", "r278", "r324", "r365", "r374", "r380" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r23", "r53", "r97", "r116", "r117", "r118", "r127", "r128", "r129", "r133", "r140", "r142", "r154", "r177", "r240", "r247", "r248", "r249", "r258", "r259", "r272", "r282", "r283", "r284", "r285", "r286", "r287", "r294", "r312", "r313", "r314" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementLineItems", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementTable", "presentation": [ "http://regenbiopharma.com/role/BalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative", "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r127", "r128", "r129", "r154", "r305" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r9", "r53", "r60" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r9", "r53", "r60" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "3/17/2023", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r8", "r9", "r53", "r60" ] }, "RGBP_StockTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "StockTransactionsTextBlock", "presentation": [ "http://regenbiopharma.com/role/StockTransactions" ], "lang": { "en-us": { "role": { "label": "STOCK TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Stockholders' Equity Attributable to Parent", "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity." } } }, "auth_ref": [ "r9", "r12", "r13", "r43", "r343", "r376", "r386", "r398" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityAbstract", "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders' Equity (Deficit)", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity." } } }, "auth_ref": [ "r63", "r64", "r66", "r97", "r98", "r117", "r127", "r128", "r129", "r133", "r140", "r177", "r240", "r247", "r248", "r249", "r258", "r259", "r272", "r282", "r283", "r287", "r294", "r313", "r314", "r376", "r386", "r398" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY", "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income." } } }, "auth_ref": [ "r61", "r124", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r240", "r270" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://regenbiopharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r301", "r302" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://regenbiopharma.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "GOING CONCERN", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r0" ] }, "RGBP_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract", "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Noncash investing and financing activities:" } } }, "auth_ref": [] }, "RGBP_TotalRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "TotalRevenues", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL REVENUES", "label": "TotalRevenues" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TypeOfArrangementAxis", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r395" ] }, "RGBP_UnearnedIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "UnearnedIncome", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Unearned Income" } } }, "auth_ref": [] }, "RGBP_UnearnedIncomeRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "UnearnedIncomeRelatedParty", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://regenbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Unearned Income (Related Party)" } } }, "auth_ref": [] }, "RGBP_UnrealizedLossgainOnInvestmentSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "UnrealizedLossgainOnInvestmentSecurities", "crdr": "credit", "calculation": { "http://regenbiopharma.com/role/StatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://regenbiopharma.com/role/StatementOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Loss (Gain) on Investment Securities", "label": "UnrealizedLossgainOnInvestmentSecurities" } } }, "auth_ref": [] }, "RGBP_UnsecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "UnsecuredPromissoryNoteMember", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://regenbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r146", "r153" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r363" ] }, "RGBP_ZanderTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://regenbiopharma.com/20240331", "localname": "ZanderTherapeuticsMember", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Zander Therapeutics" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "40", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30(a)(2))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e526-108580" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 5.T)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "730", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "230", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(16))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03.1(h))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13))", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "210", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-06(3))", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "220", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "105", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "105", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "105", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "S99", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "42", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "10", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "10", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "10", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "05", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "35", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "35", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "25", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "28", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "19", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "20", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "19", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "17", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "10", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "10", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "848", "SubTopic": "10", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "848", "SubTopic": "10", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "848", "SubTopic": "10", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "910", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "924", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "926", "SubTopic": "20", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "926", "SubTopic": "20", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "926", "SubTopic": "20", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "235", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "210", "Section": "45", "Paragraph": "20", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "210", "Section": "45", "Paragraph": "21", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "976", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "978", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)" }, "r325": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r326": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(3)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r327": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r328": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r329": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r330": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r331": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r332": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r333": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "05", "Paragraph": "5", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r334": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69B", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69C", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69E", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69F", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "55", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "55", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "55", "Paragraph": "29F", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r349": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r351": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r363": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r364": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r365": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "321", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "410", "SubTopic": "30", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "12", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "808", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "730", "Section": "25", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" } } } ZIP 54 0001607062-24-000131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-24-000131-xbrl.zip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�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end XML 56 rgbp033124form10q_htm.xml IDEA: XBRL DOCUMENT 0001589150 2023-10-01 2024-03-31 0001589150 2024-03-31 0001589150 2023-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2024-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2024-03-31 0001589150 RGBP:SeriesMMember 2023-09-30 0001589150 RGBP:SeriesMMember 2024-03-31 0001589150 RGBP:SeriesNCMember 2023-09-30 0001589150 RGBP:SeriesNCMember 2024-03-31 0001589150 2024-01-01 2024-03-31 0001589150 2023-01-01 2023-03-31 0001589150 2022-10-01 2023-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2023-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2023-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2023-09-30 0001589150 us-gaap:CommonStockMember 2023-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2023-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001589150 us-gaap:RetainedEarningsMember 2023-09-30 0001589150 RGBP:ContributedCapitalMember 2023-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2023-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-12-31 0001589150 us-gaap:CommonStockMember 2023-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001589150 us-gaap:RetainedEarningsMember 2023-12-31 0001589150 RGBP:ContributedCapitalMember 2023-12-31 0001589150 2023-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2022-09-30 0001589150 us-gaap:CommonStockMember 2022-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2022-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001589150 us-gaap:RetainedEarningsMember 2022-09-30 0001589150 RGBP:ContributedCapitalMember 2022-09-30 0001589150 2022-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2022-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-12-31 0001589150 us-gaap:CommonStockMember 2022-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001589150 us-gaap:RetainedEarningsMember 2022-12-31 0001589150 RGBP:ContributedCapitalMember 2022-12-31 0001589150 2022-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-10-01 2023-12-31 0001589150 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-10-01 2023-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001589150 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001589150 RGBP:ContributedCapitalMember 2023-10-01 2023-12-31 0001589150 2023-10-01 2023-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2024-01-01 2024-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2024-01-01 2024-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2024-01-01 2024-03-31 0001589150 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2024-01-01 2024-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001589150 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001589150 RGBP:ContributedCapitalMember 2024-01-01 2024-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-10-01 2022-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-10-01 2022-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-10-01 2022-12-31 0001589150 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-10-01 2022-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001589150 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001589150 RGBP:ContributedCapitalMember 2022-10-01 2022-12-31 0001589150 2022-10-01 2022-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2023-01-01 2023-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-01-01 2023-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-01-01 2023-03-31 0001589150 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-01-01 2023-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001589150 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001589150 RGBP:ContributedCapitalMember 2023-01-01 2023-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2024-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2024-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2024-03-31 0001589150 us-gaap:CommonStockMember 2024-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2024-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001589150 us-gaap:RetainedEarningsMember 2024-03-31 0001589150 RGBP:ContributedCapitalMember 2024-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2023-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-03-31 0001589150 us-gaap:CommonStockMember 2023-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001589150 us-gaap:RetainedEarningsMember 2023-03-31 0001589150 RGBP:ContributedCapitalMember 2023-03-31 0001589150 2023-03-31 0001589150 srt:MinimumMember 2023-10-01 2024-03-31 0001589150 srt:MaximumMember 2023-10-01 2024-03-31 0001589150 2012-07-24 2023-03-31 0001589150 RGBP:EquityLineAgreementMember 2023-09-11 2023-09-12 0001589150 RGBP:EquityLineAgreementMember 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:EquityLineAgreementMember 2023-09-11 2023-09-12 0001589150 us-gaap:CommonStockMember 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:CoventryEnterprisesLLCMember 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:EquityLineAgreementMember 2023-10-01 2023-12-31 0001589150 us-gaap:CommonStockMember RGBP:EquityLineAgreementMember 2024-01-01 2024-03-31 0001589150 RGBP:DavidKoosMember RGBP:RelatedPartyMember 2024-03-31 0001589150 RGBP:RelatedPartyMember 2024-03-31 0001589150 RGBP:DavidKoosMember 2024-03-31 0001589150 RGBP:DavidKoosMember 2023-10-01 2024-03-31 0001589150 RGBP:DueAndPayableMarch102024Member RGBP:BostoniaMember 2024-03-31 0001589150 RGBP:DueAndPayableMarch102024Member RGBP:BostoniaMember 2023-10-01 2024-03-31 0001589150 RGBP:UnsecuredPromissoryNoteMember 2023-09-11 2023-09-12 0001589150 RGBP:UnsecuredPromissoryNoteMember 2024-03-31 0001589150 RGBP:BostoniaMember RGBP:NonrelatedPartyMember 2024-03-31 0001589150 RGBP:NonrelatedPartyMember 2024-03-31 0001589150 RGBP:March82016Member 2024-03-31 0001589150 RGBP:April62016Member 2024-03-31 0001589150 RGBP:October312016Member 2024-03-31 0001589150 RGBP:May52017Member 2024-03-31 0001589150 RGBP:Dec2017Member 2024-03-31 0001589150 RGBP:Oct0317Member 2024-03-31 0001589150 RGBP:September302018Member 2024-03-31 0001589150 RGBP:DavidKoosMember 2024-03-31 0001589150 RGBP:ZanderTherapeuticsMember 2018-06-01 2018-06-11 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2018-11-01 2018-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2023-10-01 2024-03-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2023-10-01 2024-03-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2024-03-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2024-03-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2023-10-01 2024-03-31 0001589150 us-gaap:CommonStockMember 2024-01-03 0001589150 2024-01-03 0001589150 us-gaap:CommonStockMember 2024-01-10 0001589150 2024-01-10 0001589150 us-gaap:CommonStockMember 2024-02-02 0001589150 2024-02-02 0001589150 us-gaap:CommonStockMember 2024-02-21 0001589150 2024-02-21 0001589150 us-gaap:CommonStockMember 2024-03-06 0001589150 2024-03-06 0001589150 us-gaap:CommonStockMember 2024-03-20 0001589150 2024-03-20 0001589150 us-gaap:CommonStockMember 2024-04-03 0001589150 2024-04-03 iso4217:USD shares iso4217:USD shares pure 0001589150 false --09-30 2024 Q2 10-Q true 2024-03-31 false 333-191725 REGEN BIOPHARMA, INC. NV 45-5192997 4700 Spring Street St 304 La Mesa CA 91942 619 722-5505 No No Non-accelerated Filer true false 4114622 false 78115 121037 39723 0 0 200 0 5000 10000 123037 131037 17733 222580 17733 222580 140770 353617 29798 29674 49210 95710 4241 4241 342416 342588 1256630 1256630 41423 41423 1000 1000 20000 20000 1528451 1591731 0 15126 1400000 1400000 499880 499880 0 10000 5173049 5308003 143685 149614 143685 149614 5316734 5457617 0.0001 0.0001 5800000000 5800000000 4114622 3506366 412 352 0.0001 0.0001 800000000 800000000 40 40 739000000 739000000 409551 409551 0.0001 0.0001 600000 600000 34 34 0.0001 0.0001 60000000 29338 60000000 29338 0.0001 0.0001 20000 20000 15007 15007 14308349 13908141 736326 736326 -20221096 -19748863 -5175963 -5104000 140770 353617 31640 31640 63280 63280 27425 27425 54849 54849 59065 59065 118129 118129 40133 36446 87661 131959 9387 18660 21806 27398 93400 67800 200300 471480 17215 15000 32215 30000 160135 137906 341981 660837 -101071 -78842 -223852 -542708 17063 12085 34828 29444 -4339 -8706 -204847 35949 2151755 1150 -21402 23864 -248380 2123460 -122473 -54978 -472233 1580752 -122473 -54978 -472233 1391061 -0.03 -0.03 -0.12 0.41 3941013 1656429 3831431 3364578 40 0 2 352 3 13908141 -19748863 736326 -5104000 16710 2 22724 22726 35785 4 46088 46091 31732 3 38202 38205 33989 3 32626 32629 43297 4 38097 38101 82686 8 34535 34543 -349760 -349760 40 0 2 376 3 14120412 -20098623 736326 -5241463 94883 9 39629 39638 82643 8 44288 44297 40229 4 19609 19614 52569 5 32356 32362 44503 4 25278 25282 49230 5 26776 26781 -122473 -122473 40 0 2 413 3 14308349 -20221096 736326 -5175963 28 0 335 3 12132620 -20905369 736326 -8036059 6667 1 299999 300000 70114 7 761493 761500 35012 4 380258 380262 11279 1 25368 25369 1112 0 48372 48372 1635730 1635730 40 0 337 3 13648107 -19269640 736326 -4884827 15201 2 -2 0 3593 15000 2 10048 10050 -54978 -54978 40 0 2 339 3 13658153 -19324617 736326 -4929755 -472233 1580752 -348372 8706 124 5248 39723 -175150 -171 29444 -5200 -13714 0 0 -2151755 -78407 -63280 -0 1150 -204847 -371657 -63504 -10000 -61500 100000 400234 328734 100000 -42923 36949 121037 51204 78114 87700 761500 25369 380262 NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31, 2024 utilized the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zIcf9fk7bxgF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Risk Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20231001__20240331_zWH9kdMnUSl_zfZEaOIZZy0B" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">5.39</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331__srt--RangeAxis__srt--MinimumMember_zNj53BwDnzBG" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term">1.70) – (<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331__srt--RangeAxis__srt--MaximumMember_zDGCCnvztn2b" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term">4.08) Yrs</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20231001__20240331_zy9KF6FGm2IM" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate">932.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividends</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20231001__20240331_zdhUPPxMGDDd" title="Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent">100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2023 and March 31, 2024. K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31, 2024 utilized the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zIcf9fk7bxgF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Risk Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20231001__20240331_zWH9kdMnUSl_zfZEaOIZZy0B" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">5.39</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331__srt--RangeAxis__srt--MinimumMember_zNj53BwDnzBG" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term">1.70) – (<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331__srt--RangeAxis__srt--MaximumMember_zDGCCnvztn2b" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term">4.08) Yrs</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20231001__20240331_zy9KF6FGm2IM" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate">932.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividends</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zIcf9fk7bxgF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Risk Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20231001__20240331_zWH9kdMnUSl_zfZEaOIZZy0B" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">5.39</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331__srt--RangeAxis__srt--MinimumMember_zNj53BwDnzBG" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term">1.70) – (<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331__srt--RangeAxis__srt--MaximumMember_zDGCCnvztn2b" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term">4.08) Yrs</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20231001__20240331_zy9KF6FGm2IM" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate">932.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividends</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 0.0539 P1Y8M12D P4Y29D 9.3298 H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20231001__20240331_zdhUPPxMGDDd" title="Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent">100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. 1 I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2023 and March 31, 2024. 0 K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any. NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company has adopted ASU 2020-06 as of the Fiscal Year ending September 30, 2022. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements. NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,221,096 during the period from April 24, 2012 (inception) through March 31, 2024. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC (“Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”). Under the terms of the Equity Line Agreement, Coventry will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Coventry’s resale of any Common Stock purchased by Coventry under the Equity Line. From time to time over the 36-month term of the Commitment Period ( as such term is defined in the Equity Line Agreement) the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 80% of the lowest trading price of the Common Stock during the ten business days prior to the Draw Down Notice date (the “Pricing Period”). The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value (as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company. The Company issued Coventry <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230911__20230912__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zAJMcPtZRhjI">125,000 shares of its Common Stock in connection with the Equity Line Agreement. Coventry has agreed that: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right">(a)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">for so long as the market price of the Company’s common stock is above $1.25 per share and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right">(b)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company is in full compliance with all agreements entered into with Coventry and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right">(c)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">and the Company has not issued any common shares at a per share price below $1.50, Coventry will agree to a leak out provision and will not sell more than 10,000 shares of the Commitment shares without permission from the Issuer.</td> </tr></table> In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement as well as the aforementioned <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230911__20230912__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z3890FbH7kaB">125,000 common shares issued in connection with the Equity Line Agreement in a Registration Statement to be filed with the Securities and Exchange Commission. Up to <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230911__20230912__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl1TsLJ4qMo7">1,126,954 Shares of Common Stock were registered for resale under the Securities Act of 1933 pursuant to the Registration Rights Agreement. During the quarter ended December 31, 2023 the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zr6P26OKGytM">244,199 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zloceeiHAa3a">212,296. During the Quarter ended March 31, 2024 the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zYym7oVVHfZb">364,057 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zztHgIMWTaxb">187,937. 20221096 10000000 0.0001 125000 1.25 1.50 125000 1126954 244199 212296 364057 187937 NOTE 4. NOTES PAYABLE (a) RELATED PARTY <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDebtTableTextBlock_zmxk36w7c8eH" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Notes payable related party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">As of March 31, 2024</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 71%">David Koos</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_98F_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--DebtInstrumentAxis__custom--DavidKoosMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zrtQyUVio8Yy" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">710</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98A_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zeLLSiNgrgDr" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">710</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> $710 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20231001__20240331__dei--LegalEntityAxis__custom--DavidKoosMember_zJkW1LcPx6v_zVg1awkouWNm" title="Debt Instrument, Interest Rate During Period">15% per annum. (b) NON RELATED PARTY As of March 31, 2024 <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zFR1G17Oi4GH" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of non related party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 71%">Bostonia Partners, Inc</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--DebtInstrumentAxis__custom--BostoniaMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--NonrelatedPartyMember_zT874f7UnWzb" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">100.000</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_982_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--NonrelatedPartyMember_zPDZLFtqCcj8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">100,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> $48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20231001__20240331__dei--LegalEntityAxis__custom--BostoniaMember__us-gaap--LongtermDebtTypeAxis__custom--DueAndPayableMarch102024Member_zYXHy12Q8byP">10% per annum.Effective September 12, 2023 Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000 of which $26,250 was retained by Coventry through an Original Issue Discount. The Note carries “Guaranteed Interest” on the principal amount at the rate of 10% per annum for the eighteen-month term of the Note for an aggregate Guaranteed Interest $26,250. The Principal Amount and the Guaranteed Interest shall be due and payable in seven equal monthly payments of $28,750 commencing on August 12, 2024 and continuing on the 12th day of each month thereafter until paid in full not later than March 12, 2025(the “Maturity Date”). Upon an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder at price per share equivalent to 90% of the lowest per-share trading price for the 20 Trading Days preceding a Conversion Date. Upon the event that while this Note has been outstanding for four months, the Company consummates another financing transaction or if the Company has an effective Regulation A Offering Statement then the Investor may choose to convert any amount up to the entire balance of the note including guaranteed interest into shares at the same offering price as the aforementioned financing transaction or the Regulation A Offering. The outstanding principal balance of the Note is $160,000 as of March 31, 2024. <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfDebtTableTextBlock_zmxk36w7c8eH" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Notes payable related party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">As of March 31, 2024</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 71%">David Koos</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_98F_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--DebtInstrumentAxis__custom--DavidKoosMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zrtQyUVio8Yy" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">710</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98A_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zeLLSiNgrgDr" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">710</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> 710 710 710 0.15 <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zFR1G17Oi4GH" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of non related party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 71%">Bostonia Partners, Inc</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--DebtInstrumentAxis__custom--BostoniaMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--NonrelatedPartyMember_zT874f7UnWzb" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">100.000</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_982_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--NonrelatedPartyMember_zPDZLFtqCcj8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">100,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> 100.000 100000 48500 0.10 175000 26250 26250 28750 160000 NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_c20240331__us-gaap--DebtInstrumentAxis__custom--March82016Member_zoigCqnFWayb" title="Debt Instrument, Interest Rate, Effective Percentage">8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property As of March 31, 2024 $100,000 of the principal amount of the Note remains outstanding. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20240331__us-gaap--DebtInstrumentAxis__custom--April62016Member_zrTF2Rm5pvfT" title="Debt Instrument, Interest Rate, Effective Percentage">8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or$150 per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property As of March 31, 2024 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. As of March 31, 2024 $50,000 of the principal amount of the Note remains outstanding On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20240331__us-gaap--DebtInstrumentAxis__custom--May52017Member_zAEDyBzaD2tZ" title="Debt Instrument, Interest Rate, Effective Percentage">10% per annum . The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $375 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iii) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $75 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of March 31, 2024 $200,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,000 was recognized by the Company as of March 31, 2024. On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20240331__us-gaap--DebtInstrumentAxis__custom--Dec2017Member_zMNa9XHjRC43" title="Debt Instrument, Interest Rate, Effective Percentage">10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.50 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $37.5 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of March 31, 2024 $100,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,000 was recognized by the Company as of March 31, 2024. On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20240331__us-gaap--DebtInstrumentAxis__custom--Oct0317Member_zw8LvDiyfDkf" title="Debt Instrument, Interest Rate, Effective Percentage">10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.5 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $37.5 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of March 31, 2024, $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of March 31, 2024. 100000 100000 0.08 100000 50000 50000 8 50000 50000 200000 200000 10 200000 800000 100000 100000 10 100000 400000 50000 50000 10 50000 200000 NOTE 6. RELATED PARTY TRANSACTIONS On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby: 1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement. 2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement. 3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement. No actions were taken by any of the parties to enforce the terms of the Agreement. On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be: a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto. Zander and Regen are under common control. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of March 31, 2024, $0 of the principal amount of the Note remains outstanding and all accrued interest has been paid. On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of : a) Reviewing existing publications on research being conducted on Checkpoint NR2F6. b) Identifying the most promising applications for the Company’s technology c) Drafting a “white paper” on results for 1(b) d) Making introductions to known experts in appropriate fields identified in 1(b). Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275 and during the quarter ended June 30, 2022 Dr. Brian Koos was paid $36,975. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company. As of March 31, 2024 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $<span id="xdx_90F_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20240331__us-gaap--DebtInstrumentAxis__custom--DavidKoosMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zp2jlfteRevo" title="Notes Payable, Related Parties, Current">710. $710 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc. 350000 0 710 710 NOTE 7. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of March 31, 2024: Common stock, $ 0.0001 par value; 5,800,000,000 shares authorized: 4,114,622 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zXLMUCGcUxJ_zbTtx7pVj3vk" title="Preferred Stock, Shares Authorized">600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of March 31, 2024, 739,000,000 is designated Series A Preferred Stock of which 409,551 shares are outstanding as of March 31, 2024, 60,000,000 is designated Series M Preferred Stock of which 29,338 shares are outstanding as of March 31, 2024, and 20,000 is designated Series NC stock of which 15,007 shares are outstanding as of March 31, 2024. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times seven (7). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 739,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series M Preferred Stock” (hereinafter referred to as “Series M Preferred Stock”). The Board of Directors of Regen have authorized 60,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as “Series NC Preferred Stock”). The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 334. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. 5800000000 4114622 0.0001 800000000 600000 34 739000000 409551 60000000 29338 20000 15007 NOTE 8. INVESTMENT SECURITIES, RELATED PARTY On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of <span id="xdx_900_ecustom--NumberOfSharesIssuedForPropertyDividend_c20180601__20180611__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zezNG4ny5pT_z3YOgqWWudnZ" title="Number Of Shares Issued For Property Dividend">470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted <span id="xdx_90E_ecustom--NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest_c20181101__20181129__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z3niLSHcdadH" title="Number Of Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest">725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $<span id="xdx_905_ecustom--SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue_pp0p0_c20181101__20181129__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z6Q6h3fghE3C" title="Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest Value">13,124. On March 31, 2024 the Company revalued <span id="xdx_909_ecustom--NumberOfSharesIssuedForPropertyDividend_c20231001__20240331__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zHNpQ5AtAbYF" title="Number Of Shares Issued For Property Dividend">470,588 of the common shares of Zander Therapeutics, Inc. and <span id="xdx_901_ecustom--NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest_c20231001__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zSNLJE2NcaUx" title="Number Of Shares Issued In Satisfaction Of Prepaid Rent And Accrued Interest">725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_z5XwnwJartEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Fair Value of Intellectual Property</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueOfIntellectualProperty_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zge4WkpoPhsZ" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Fair Value of Intellectual Property">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--PrepaidExpenseCurrent_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zYzGRHGv37R_znInbeZrKFPY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expense, Current">65,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due from Employee</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--DueFromEmployeeRelatedParty_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zV0dWHyeMVXm" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Due from Employees">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ReceivablesNetCurrent_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z4dvV0d7Fb_zkgKzlA7lEHk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Receivables, Net, Current">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Interest Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccruedInvestmentIncomeReceivable_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z30vd9KRUEGo" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Investment Income Receivable">35,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment Securities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--Investments_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zmlwdD9AYlv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investments">258,255</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ConvertibleNoteReceivable_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zKhUthUdeWSu" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible Note Receivable">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zVXSdzytE73T" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accounts Payable, Current">30,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zs1j0L9kChDN" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payables">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses Related Parties</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--AccruedExpensesRelated_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z59199FcECjQ" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Expenses, Related Party">162,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable Related Party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--NotesPayableRelatedPartyClassifiedCurrent_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zkvWh67kJv6z" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable, Related Parties, Current">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zlBsX3T5YJBj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Liabilities, Current">647,072</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Enterprise Value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--EnterpriseValue_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zFS85smQeS5A" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enterprise Value">1,948,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less: Total Debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtCurrent_iNI_pp0p0_di_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z9m4Fv63IwMp" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Current">(1,239,646</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Portion of Enterprise Value Attributable to Shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--PortionOfEnterpriseValueAttributableToShareholders_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z9NXbA0Avi1O" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Portion of Enterprise Value attributable to Shareholders">708,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value Per Share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--FairValuePerShare_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zlRZB25sL2jt" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value per share">0.0155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The abovementioned constitute the Company’s sole related party investment securities as of March 31, 2024. As of March 31, 2024: <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_ztitxh23GB8J" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Comprehensive income</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">470,588 Common Shares of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%; vertical-align: bottom">Total Unrealized Gains</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_984_ecustom--InvestmentSecuritiesBasis_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zlLMkEDYrbWl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">5,741</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_987_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zIeuVIs3kcXu" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">6,496</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_987_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zH6ws4ESi4if" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">755</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pp0p0_c20231001__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zA6TCn3ThMQ_zlb0gCgfgIaa" title="Investment Securities, net Unrealized Gain or (Loss) realized">(0</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">725,000 Series M Preferred of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Total Unrealized Loss</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zz0DN7693ZDZ" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">13,124</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_983_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zmP5Ac6mcoZY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">11,238</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_986_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zowuIaWqA1Pj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">(1,866</td> <td style="font: 10pt Times New Roman, Times, Serif">) </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pp0p0_c20231001__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_znFImuCoELUV" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, net Unrealized Gain or (Loss) realized">(0</td> <td style="font: 10pt Times New Roman, Times, Serif">) </td></tr> </table> 470588 725000 13124 470588 725000 <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_z5XwnwJartEh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Fair Value of Intellectual Property</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueOfIntellectualProperty_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zge4WkpoPhsZ" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Fair Value of Intellectual Property">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--PrepaidExpenseCurrent_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zYzGRHGv37R_znInbeZrKFPY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expense, Current">65,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due from Employee</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--DueFromEmployeeRelatedParty_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zV0dWHyeMVXm" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Due from Employees">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ReceivablesNetCurrent_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z4dvV0d7Fb_zkgKzlA7lEHk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Receivables, Net, Current">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Interest Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccruedInvestmentIncomeReceivable_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z30vd9KRUEGo" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Investment Income Receivable">35,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment Securities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--Investments_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zmlwdD9AYlv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investments">258,255</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ConvertibleNoteReceivable_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zKhUthUdeWSu" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible Note Receivable">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zVXSdzytE73T" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accounts Payable, Current">30,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zs1j0L9kChDN" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payables">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses Related Parties</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--AccruedExpensesRelated_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z59199FcECjQ" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Expenses, Related Party">162,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable Related Party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--NotesPayableRelatedPartyClassifiedCurrent_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zkvWh67kJv6z" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable, Related Parties, Current">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrent_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zlBsX3T5YJBj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Liabilities, Current">647,072</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Enterprise Value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--EnterpriseValue_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zFS85smQeS5A" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enterprise Value">1,948,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less: Total Debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtCurrent_iNI_pp0p0_di_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z9m4Fv63IwMp" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Current">(1,239,646</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Portion of Enterprise Value Attributable to Shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--PortionOfEnterpriseValueAttributableToShareholders_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_z9NXbA0Avi1O" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Portion of Enterprise Value attributable to Shareholders">708,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value Per Share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--FairValuePerShare_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zlRZB25sL2jt" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value per share">0.0155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 300000 65661 0 40000 35000 258255 10000 30563 400000 162011 0 647072 1948562 1239646 708916 0.0155 <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_ztitxh23GB8J" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Comprehensive income</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">470,588 Common Shares of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%; vertical-align: bottom">Total Unrealized Gains</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_984_ecustom--InvestmentSecuritiesBasis_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zlLMkEDYrbWl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">5,741</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_987_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zIeuVIs3kcXu" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">6,496</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_987_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zH6ws4ESi4if" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">755</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pp0p0_c20231001__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zA6TCn3ThMQ_zlb0gCgfgIaa" title="Investment Securities, net Unrealized Gain or (Loss) realized">(0</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">725,000 Series M Preferred of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Total Unrealized Loss</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended March 31, 2024</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: bottom"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zz0DN7693ZDZ" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">13,124</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_983_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zmP5Ac6mcoZY" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">11,238</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_986_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_pp0p0_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zowuIaWqA1Pj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">(1,866</td> <td style="font: 10pt Times New Roman, Times, Serif">) </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pp0p0_c20231001__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_znFImuCoELUV" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, net Unrealized Gain or (Loss) realized">(0</td> <td style="font: 10pt Times New Roman, Times, Serif">) </td></tr> </table> 5741 6496 755 -0 13124 11238 -1866 -0 NOTE 9. STOCK TRANSACTIONS On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638. On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $44,297. On February 2, 2024 the Company issued 40,229 common shares for cash consideration of $19,614. On February 21, 2024 the Company issued 52,569 common shares for cash consideration of $32,362. On March 6, 2024 the Company issued 44,503 common shares for cash consideration of $25,282. On March 20, 2024 the Company issued 49,230 common shares for cash consideration of $26,781. 94883 39638 82643 44297 40229 19614 52569 32362 44503 25282 49230 26781 NOTE 10. SUBSEQUENT EVENTS On April 3, 2024 the Company issued 52,763 common shares for cash consideration of $25,326. 52763 25326